---

Diabetes Mellitus - Complete Clinical Reference

---

1. DEFINITION

"Diabetes mellitus is a heterogeneous spectrum of metabolic disorders, likely arising from disparate genetic and environmental factors, with a common outcome of impaired glucose homeostasis and hyperglycemia."

• Goodman & Gilman's Pharmacological Basis of Therapeutics

---

2. TYPES / CLASSIFICATION

Type 1 Diabetes Mellitus (T1DM)

• Autoimmune destruction of pancreatic β-cells leading to absolute insulin deficiency
• Accounts for 5-10% of all diabetes cases
• Previously called "juvenile-onset" or "insulin-dependent" - both terms now discouraged (can present at any age; T2DM may also need insulin)
• Strong HLA associations; most cases sporadic with defined genetic risk

Type 2 Diabetes Mellitus (T2DM)

• Characterized by impaired insulin secretion + insulin resistance
• Accounts for >90% of all diabetes cases
• Strong polygenic hereditary component; influenced by obesity and sedentary lifestyle
• May present in obese children and adolescents (not just adults)
• Previously called "adult-onset" or "non-insulin-dependent" - both terms now discouraged

Gestational Diabetes Mellitus (GDM)

• Glucose intolerance first recognized during pregnancy
• Affects ~2-10% of pregnant women; rising with obesity prevalence
• Results from impaired β-cell compensation for physiologic insulin resistance of pregnancy (placenta secretes diabetogenic hormones: growth hormone, human placental lactogen, corticotropin-releasing hormone, progesterone)
• Usually resolves after delivery; up to 60% lifetime risk of progressing to T2DM

Other Specific Types

---

3. CAUSES / ETIOLOGY

T1DM Causes

• Autoimmune: CD4+ and CD8+ T-lymphocyte-mediated destruction of β-cells; islet-cell autoantibodies (anti-GAD65, anti-IA-2, anti-ZnT8, anti-insulin antibodies) are markers
• Genetic susceptibility: HLA class II alleles (HLA-DR3, HLA-DR4, HLA-DQ) confer highest risk; MHC class I alleles (HLA-A, HLA-B, HLA-C) also contribute
• Environmental triggers: Viral infections (enterovirus, Coxsackie B, mumps, CMV, congenital rubella); dietary factors; gut microbiome alterations - precise triggers remain largely unknown
• Non-immune (LADA): Latent autoimmune diabetes in adults - slower progression than classic T1DM

T2DM Causes

1. Peripheral insulin resistance - skeletal muscle, liver, adipose tissue
2. β-cell dysfunction - inadequate compensatory insulin secretion

• Obesity (central/visceral adiposity) - the most important modifiable risk factor; risk rises with increasing BMI
• Free fatty acids (FFAs): Central adipose tissue liberates excess FFAs → diacylglycerol (DAG), ceramide, and sphingolipid accumulation → impaired insulin receptor tyrosine phosphorylation → reduced GLUT-4 translocation → hyperglycemia
• Adipokines: Leptin resistance, reduced adiponectin, elevated TNF-α and IL-6 from adipose tissue
• Amyloid deposition: IAPP (islet amyloid polypeptide) deposits in islets of patients with T2DM impairs β-cell function
• Glucotoxicity and lipotoxicity: Chronic hyperglycemia and FFAs further impair β-cell secretory capacity
• Sedentary lifestyle; aging; family history (strong polygenic component)

---

4. PATHOLOGY

Normal Glucose Homeostasis (Relevant Background)

• Fasting: liver provides glucose via glycogenolysis and gluconeogenesis (regulated by insulin-glucagon ratio); most tissues oxidize fatty acids
• Prandial: nutrient absorption triggers incretin release (GLP-1, GIP) → insulin secretion from β-cells → glucose uptake by liver, muscle, adipose tissue; hepatic glucose production suppressed
• β-cells precisely adjust insulin output to maintain euglycemia

T1DM Pathology

• HLA-DR3 or HLA-DR4 confer susceptibility; HLA-DQ alleles are even stronger risk markers
• Non-HLA genes (e.g., INS VNTR, PTPN22, CTLA4) also contribute

• Viral infections may trigger β-cell autoimmunity via molecular mimicry or bystander activation
• The "hygiene hypothesis" proposes reduced childhood microbial exposure increases risk

• CD4+ T helper cells sensitize → CD8+ cytotoxic T cells directly kill β-cells
• Islet infiltration by lymphocytes = insulitis (pathognomonic finding on biopsy)
• Progressive loss of β-cell mass over years before clinical presentation
• Autoantibodies (anti-GAD65 most sensitive; anti-IA-2, anti-ZnT8, anti-insulin) precede symptoms by years

• Reduced number and size of islets
• Lymphocytic infiltration (insulitis)
• Relative predominance of α and δ cells as β-cells are selectively destroyed

T2DM Pathology

• Reduced tyrosine phosphorylation of insulin receptor substrate (IRS) proteins
• Decreased GLUT-4 expression/translocation in skeletal muscle
• FFA intermediates (DAG, ceramide) activate serine kinases (PKC, IKK-β) that phosphorylate IRS on serine residues → impaired downstream signaling
• Liver: failure to suppress gluconeogenesis → elevated fasting glucose
• Skeletal muscle: failure of postprandial glucose uptake → elevated postprandial glucose
• Adipose tissue: failure to suppress hormone-sensitive lipase → excess FFA release

• Initially: compensatory β-cell hyperfunction and hyperinsulinemia
• Over time: ~50% of β-cell mass lost by the time of T2DM diagnosis
• Mechanisms of β-cell loss: amyloid (IAPP) deposition in islets (pathognomonic histological finding in T2DM), FFA lipotoxicity, oxidative stress, glucotoxicity, inflammatory cytokines

• Islet amyloid deposits (IAPP-derived amyloid) - virtually diagnostic of T2DM on histology
• Reduced β-cell mass
• No insulitis (unlike T1DM)
• Islet fibrosis in long-standing disease

Pathology of Chronic Complications (Morphology)

• Accelerated atherosclerosis in aorta, coronary arteries, and large peripheral vessels
• Same lesions as non-diabetics but earlier onset, more severe, more diffuse
• Contributes to MI, stroke, peripheral arterial disease

• Diffuse thickening of basement membranes (capillary walls) throughout the body
• Most clinically important in retina and kidney
• Mechanism: non-enzymatic glycation of basement membrane proteins, increased polyol pathway flux, PKC activation, oxidative stress, advanced glycation end-products (AGEs)

• Glomerular changes: diffuse glomerulosclerosis (most common) and nodular glomerulosclerosis (Kimmelstiel-Wilson nodules - pathognomonic)
• Efferent arteriolar hyalinosis (more specific for DM than afferent)
• Progression: microalbuminuria → macroalbuminuria → proteinuria → declining GFR → ESRD
• Leading cause of ESRD in the United States

• Background (non-proliferative): microaneurysms, hemorrhages, exudates, macular edema
• Proliferative: neovascularization on retinal surface (due to VEGF), vitreous hemorrhage, retinal detachment → blindness
• Leading cause of adult-onset blindness in the United States

• Distal symmetric sensorimotor polyneuropathy (most common): "stocking-glove" distribution; loss of vibration, proprioception, pain → Charcot joint, foot ulcers
• Autonomic neuropathy: orthostatic hypotension, gastroparesis, neurogenic bladder, erectile dysfunction, impaired sweating
• Cranial and focal mononeuropathies: oculomotor palsy (CN III most common), carpal tunnel syndrome

---

5. DIAGNOSTIC APPROACH

Diagnostic Criteria (ADA/WHO)

• In the absence of unequivocal hyperglycemia, criteria should be confirmed by repeat testing on a different day
• FPG: no caloric intake for at least 8 hours
• HbA1c must be performed by an NGSP-certified method traceable to the DCCT reference assay
• These criteria do not apply to gestational diabetes

Screening Recommendations (ADA)

• Age >45 years (repeat every 3 years if normal)
• BMI >25 kg/m² (or >23 in Asian descent) with any of: family history, physical inactivity, high-risk ethnicity (African American, Latino, Native American, Asian American, Pacific Islander), history of GDM, polycystic ovary syndrome, hypertension, HDL <35 mg/dL or TG >250 mg/dL, history of cardiovascular disease
• Patients with prediabetes: test annually
• Women with prior GDM: test at least every 3 years

Additional Workup

• C-peptide: Low/undetectable in T1DM; normal/elevated in T2DM or insulinoma
• Islet autoantibodies (anti-GAD65, anti-IA-2, anti-ZnT8, anti-insulin): confirm T1DM autoimmune etiology
• Urinalysis/urine albumin-to-creatinine ratio: screen for nephropathy
• Lipid panel, blood pressure: cardiovascular risk assessment
• Thyroid function: T1DM patients (increased risk of autoimmune thyroid disease)
• Genetic testing: in suspected MODY (young, non-obese, strong family history, absent autoantibodies)

Continuous Glucose Monitoring (CGM)

---

6. MANAGEMENT

Goals of Therapy

1. Alleviate symptoms (fatigue, polyuria, polydipsia, weight loss)
2. Prevent acute metabolic decompensation (DKA, HHS)
3. Prevent/delay chronic microvascular and macrovascular complications
4. Allow normal life activities and improve quality of life

• HbA1c <7% for most adults (individualized: <6.5% if achievable without significant hypoglycemia; up to <8% for elderly/frail or those with comorbidities)
• Fasting glucose: 80-130 mg/dL; peak postprandial <180 mg/dL

Non-Pharmacological Management

• Medical Nutrition Therapy (MNT): reduced caloric intake; low glycemic index foods; reduced saturated/trans fats; increased dietary fiber; carbohydrate counting (important for insulin dosing in T1DM)
• Physical activity: ≥150 min/week of moderate-intensity aerobic exercise + resistance training; exercise improves insulin sensitivity by increasing GLUT-4 translocation to skeletal muscle plasma membranes
• Weight loss in T2DM: 5-10% weight loss improves glycemia, blood pressure, lipids; ≥15% may induce T2DM remission
• Smoking cessation; self-monitoring of blood glucose; diabetes education and self-management support
• Bariatric surgery: highly effective for T2DM remission in eligible obese patients (BMI ≥35)

• Intensive lifestyle intervention (DPP trial): reduces incident diabetes by ~58%
• Metformin (1g BID): reduces risk by ~25%
• Acarbose (up to 100mg TID): reduces short-term risk by ~25%
• Liraglutide 3 mg/day: reduces incident diabetes by ~20% in overweight patients with prediabetes

---

7. PHARMACOLOGY

A. INSULIN THERAPY

• T1DM regimens: Basal-bolus (multiple daily injections) or continuous subcutaneous insulin infusion (CSII/insulin pump); closed-loop systems (artificial pancreas) increasingly available
• T2DM: Start with basal insulin (bedtime glargine/detemir); add prandial insulin as needed

---

B. NON-INSULIN AGENTS (T2DM)

1. Biguanides - Metformin

• Mechanism: Activates AMPK → inhibits hepatic gluconeogenesis; also reduces intestinal glucose absorption; mild peripheral insulin sensitization; does NOT stimulate insulin secretion
• Benefits: No hypoglycemia, mild weight loss or neutral, cardioprotective data, inexpensive, may prevent diabetes
• Adverse effects: GI (nausea, diarrhea - reduce with titration); lactic acidosis (rare, mainly in renal impairment); Vitamin B12 deficiency with long-term use
• Contraindications: eGFR <30 mL/min; hold before iodinated contrast/surgery
• Dosing: Start 500mg daily with meals; max 2,550 mg/day in divided doses

2. Sulfonylureas (2nd generation)

• Drugs: Glimepiride, Glipizide, Glyburide
• Mechanism: Bind SUR1 subunit of β-cell K_ATP channel → channel closure → membrane depolarization → Ca²+ influx → insulin secretion (glucose-independent)
• Benefits: Potent glucose lowering; inexpensive
• Adverse effects: Hypoglycemia (major risk, especially glyburide), weight gain (1-3 kg)
• Contraindications: T1DM, renal/hepatic insufficiency, pregnancy

3. Meglitinides (Non-sulfonylurea secretagogues)

• Drugs: Repaglinide, Nateglinide
• Mechanism: Same as sulfonylureas (K_ATP closure) but bind different site; shorter duration
• Use: Target postprandial hyperglycemia; flexible dosing (take with each meal, skip if meal skipped)
• Adverse effects: Hypoglycemia (less than sulfonylureas), weight gain

4. Thiazolidinediones (TZDs/Glitazones)

• Drugs: Pioglitazone, Rosiglitazone
• Mechanism: Agonists of PPARγ (peroxisome proliferator-activated receptor-γ) in adipose tissue → increased adiponectin, improved insulin sensitivity in muscle and liver; redistribution of fat from visceral to subcutaneous
• Benefits: No hypoglycemia; pioglitazone has modest cardiovascular benefit (PROACTIVE trial)
• Adverse effects: Weight gain (2-4 kg), fluid retention/edema, congestive heart failure exacerbation, bone fractures (increased risk in women), bladder cancer risk (pioglitazone - long-term use)
• Contraindications: Heart failure (NYHA Class III/IV), active bladder cancer

5. GLP-1 Receptor Agonists (Incretin mimetics)

• Drugs: Liraglutide, Semaglutide (daily and weekly SC), Exenatide, Dulaglutide, Albiglutide; oral semaglutide available
• Mechanism: Mimic endogenous GLP-1 → stimulate glucose-dependent insulin secretion → suppress glucagon → slow gastric emptying → central satiety signals → weight loss
• Key benefits: Significant weight loss (5-15%); CV risk reduction (liraglutide - LEADER trial; semaglutide - SUSTAIN-6); no hypoglycemia as monotherapy; GLP-1/GIP dual agonist tirzepatide (Mounjaro) shows superior glycemic and weight-loss outcomes
• Adverse effects: Nausea, vomiting, diarrhea (main); pancreatitis (rare); C-cell thyroid tumors (rodent data - contraindicated in MEN-2/medullary thyroid cancer)
• Route: Subcutaneous injection (daily or weekly); oral semaglutide available

6. DPP-4 Inhibitors (Gliptins)

• Drugs: Sitagliptin, Saxagliptin, Alogliptin, Linagliptin
• Mechanism: Inhibit dipeptidyl peptidase-4 → prevent degradation of endogenous GLP-1 and GIP → modest glucose-dependent insulin secretion and glucagon suppression
• Benefits: Weight neutral; low hypoglycemia risk; oral; renal-dose adjustment available (except linagliptin)
• Adverse effects: Nasopharyngitis, urinary tract infections; rare pancreatitis; saxagliptin: possible increased HF hospitalization (SAVOR-TIMI trial)

7. SGLT-2 Inhibitors (Gliflozins)

• Drugs: Empagliflozin, Canagliflozin, Dapagliflozin
• Mechanism: Inhibit sodium-glucose cotransporter-2 (SGLT-2) in the proximal renal tubule → reduce glucose reabsorption → glycosuria (~60-80g glucose/day excreted)
• Key benefits: Weight loss (2-3 kg); BP reduction; dramatic cardiovascular outcome benefits (empagliflozin - EMPA-REG; canagliflozin - CANVAS); nephroprotective (dapagliflozin - DAPA-CKD; canagliflozin - CREDENCE); heart failure benefit (empagliflozin - EMPEROR-Reduced)
• Adverse effects: Genitourinary infections (candidiasis, UTI); euglycemic DKA (rare but serious; hold perioperatively); volume depletion; Fournier's gangrene (rare); lower limb amputations (canagliflozin - requires monitoring); bone fractures (canagliflozin)
• Contraindications: eGFR <20-30 (varies by agent); T1DM (risk of euglycemic DKA unless specific protocols)

8. Alpha-glucosidase Inhibitors

• Drugs: Acarbose, Miglitol
• Mechanism: Competitively inhibit intestinal α-glucosidase enzymes → delay carbohydrate digestion and absorption → blunt postprandial glucose rise
• Benefits: No hypoglycemia; no systemic absorption; reduces postprandial glucose
• Adverse effects: Flatulence, bloating, diarrhea (major tolerability issue); rare hepatotoxicity with high doses

9. Amylin Analogs

• Drug: Pramlintide
• Mechanism: Synthetic amylin analog → suppresses postprandial glucagon, slows gastric emptying, central satiety → reduces postprandial glucose
• Use: Adjunct to mealtime insulin in T1DM and T2DM
• Adverse effects: Nausea; hypoglycemia (requires insulin dose reduction)

C. MANAGEMENT OF T1DM - KEY PRINCIPLES

• All T1DM patients require lifelong insulin therapy
• Preferred: basal-bolus regimen (long-acting basal + rapid-acting at meals)
• Insulin pump (CSII) with CGM provides the best glycemic control
• Closed-loop systems (hybrid artificial pancreas) are becoming standard
• Monitor for thyroid disease, celiac disease, Addison's disease (associated autoimmune conditions)
• Immunotherapy (anti-CD3; teplizumab) can delay T1DM onset in high-risk individuals (FDA-approved 2022)

D. STEPWISE APPROACH TO T2DM PHARMACOTHERAPY

1. Lifestyle modification + Metformin (unless contraindicated)
2. Add second agent based on patient profile:
   • CVD present/high ASCVD risk: Add GLP-1 RA (liraglutide, semaglutide) or SGLT-2 inhibitor (empagliflozin, canagliflozin)
   • Heart failure or CKD: Add SGLT-2 inhibitor
   • Weight loss needed: GLP-1 RA preferred
   • Minimize hypoglycemia: DPP-4 inhibitor, GLP-1 RA, or SGLT-2 inhibitor
   • Cost concern: Sulfonylurea or TZD
3. Add third agent if HbA1c remains above target
4. Progress to insulin (basal first, then basal-bolus) when oral/injectable agents insufficient

---

8. COMPLICATIONS

Acute Complications

Diabetic Ketoacidosis (DKA)

• Primarily T1DM (rare in T2DM)
• Precipitants: missed insulin, infection, stress, new diagnosis
• Pathophysiology: absolute insulin deficiency → unrestrained glucagon → hyperglycemia + accelerated lipolysis → ketogenesis (acetoacetate, β-hydroxybutyrate) → metabolic acidosis
• Clinical features: Polyuria, polydipsia, nausea/vomiting, abdominal pain, Kussmaul breathing (deep, rapid), fruity (acetone) breath, altered consciousness
• Diagnosis: Blood glucose >250 mg/dL, pH <7.3, bicarbonate <18 mEq/L, positive ketones (urine/serum), anion gap metabolic acidosis
• Management: IV fluids (0.9% NaCl first), insulin infusion (regular insulin), potassium replacement (never give insulin without ensuring K+ >3.5), treat precipitant; transition to SC insulin when anion gap closes

Hyperosmolar Hyperglycemic State (HHS)

• Primarily T2DM (older patients with residual insulin to prevent ketosis)
• Precipitants: infection, dehydration, stroke, inadequate fluid intake
• Pathophysiology: relative insulin deficiency → severe hyperglycemia → osmotic diuresis → profound dehydration without significant ketoacidosis
• Diagnosis: Blood glucose >600 mg/dL, serum osmolality >320 mOsm/kg, minimal/no ketosis, pH >7.3
• Management: Aggressive IV fluid replacement; insulin after initial resuscitation; treat precipitant; mortality higher than DKA (5-20%)

Hypoglycemia

• Most common acute complication of DM treatment (insulin, sulfonylureas)
• Blood glucose <70 mg/dL (ADA threshold); severe <54 mg/dL
• Symptoms: autonomic (sweating, tremor, palpitations, anxiety) then neuroglycopenic (confusion, seizure, coma)
• Treatment: 15g fast-acting carbohydrate (rule of 15); glucagon (SC/IM/intranasal) or IV dextrose for severe cases
• Hypoglycemia unawareness: loss of autonomic warning symptoms (adrenergic) with recurrent hypoglycemia; dangerous - managed with strict avoidance of hypoglycemia (hypoglycemia-associated autonomic failure reversal)

Chronic Complications

Microvascular Complications

• Most common cause of blindness in working-age adults in developed countries
• Stages: mild non-proliferative → moderate non-proliferative → severe non-proliferative → proliferative diabetic retinopathy (PDR)
• Features: microaneurysms, dot/blot hemorrhages, hard exudates, cotton-wool spots (nerve fiber infarcts), venous beading, intraretinal microvascular abnormalities (IRMA), neovascularization, vitreous hemorrhage, traction retinal detachment
• Diabetic macular edema (DME) can occur at any stage; most common cause of visual loss
• Screening: annual fundoscopy from diagnosis (T2DM); from 5 years after diagnosis in T1DM (or at puberty)
• Treatment: strict glycemic/BP control; anti-VEGF injections (ranibizumab, bevacizumab) for PDR and DME; laser photocoagulation; vitrectomy

• Leading cause of ESRD in the United States
• Progression: glomerular hyperfiltration → microalbuminuria (30-300 mg/day) → macroalbuminuria (>300 mg/day) → progressive decline in GFR → ESRD
• Histology: mesangial expansion, glomerular BM thickening, diffuse glomerulosclerosis, Kimmelstiel-Wilson nodules (nodular glomerulosclerosis - pathognomonic), afferent and efferent arteriolar hyalinosis (efferent more specific)
• Screening: annual urine albumin-to-creatinine ratio (UACR) and eGFR
• Treatment: ACE inhibitors or ARBs (first-line, independently of blood pressure in patients with microalbuminuria); SGLT-2 inhibitors (nephroprotective - CREDENCE, DAPA-CKD trials); strict glycemic and BP control (<130/80 mmHg)

• Most common complication of DM; affects ~50% of patients with >25-year duration
• Types:
  • Distal symmetric polyneuropathy (most common): stocking-glove sensory loss; risk of painless foot ulceration, Charcot arthropathy
  • Painful neuropathy: burning, stabbing, shooting pain (worse at night)
  • Autonomic neuropathy: gastroparesis, neurogenic bladder, erectile dysfunction, orthostatic hypotension, resting tachycardia, cardiac denervation
  • Mononeuropathies: cranial nerve palsies (CN III most common - spared pupil), carpal tunnel, meralgia paresthetica
  • Diabetic amyotrophy (Bruns-Garland): proximal lower limb weakness/pain
• Treatment: strict glycemic control (primary prevention); pain management: tricyclic antidepressants, duloxetine (FDA-approved), pregabalin/gabapentin, topical capsaicin; foot care education

Macrovascular Complications

• Coronary artery disease (CAD): 2-4x increased risk; major cause of death in T2DM; silent MI more common due to autonomic neuropathy
• Cerebrovascular disease (stroke): 2-4x increased risk of ischemic stroke
• Peripheral arterial disease (PAD): critical limb ischemia; diabetic foot syndrome (neuropathy + ischemia + infection → ulceration/gangrene → amputation)
• Diabetic foot: Leading cause of non-traumatic lower extremity amputation
• Management of macrovascular disease: antiplatelet therapy (aspirin for secondary prevention); statins (LDL target <70 mg/dL for high-risk); aggressive BP control (target <130/80 mmHg); ACE inhibitor/ARB; GLP-1 RA and SGLT-2 inhibitors for patients with established CVD

Other Complications

• Infections: Increased susceptibility (impaired neutrophil function, complement deficiency); susceptible to unusual infections: Mucormycosis (rhinocerebral), emphysematous cholecystitis, malignant otitis externa (Pseudomonas), Fournier's gangrene
• Non-alcoholic fatty liver disease (NAFLD)/NASH: Closely associated with T2DM and insulin resistance
• Skin manifestations: Acanthosis nigricans (insulin resistance), necrobiosis lipoidica diabeticorum, diabetic dermopathy, bullosis diabeticorum
• Cataracts and glaucoma: Increased risk
• Erectile dysfunction: ~50% of men with diabetes >10 years

---

Summary Table: T1DM vs T2DM

---

• Robbins & Cotran Pathologic Basis of Disease (10th ed.) - Chapter 24: Endocrine System
• Goldman-Cecil Medicine (International Edition) - Chapter 210: Diabetes Mellitus
• Goodman & Gilman's Pharmacological Basis of Therapeutics (13th ed.) - Chapter 51: Pancreatic Islet Hormones
• Harrison's Principles of Internal Medicine (22nd ed., 2025) - Chapter 415: Diabetes Mellitus
• Guyton & Hall Textbook of Medical Physiology - Chapter 79: Insulin, Glucagon, and Diabetes Mellitus
• ADA Standards of Care in Diabetes - 2024

Recent Evidence Note: A 2024 systematic review (PMID 39572394, Age & Ageing) highlights the need to individualize glycemic targets for older/frail patients with T2DM, recommending less stringent HbA1c goals (up to 8-9%) to minimize hypoglycemia risk.This comprehensive reference synthesizes content from six major medical textbooks. Here's a quick orientation to what's covered:

---

1. Definition - Precise metabolic definition with epidemiological scope
2. Types - T1DM, T2DM, GDM, and full WHO/ADA classification of "other specific types" including MODY, drug-induced, endocrinopathic, and rare genetic forms
3. Causes/Etiology - Autoimmune mechanisms (T1DM), insulin resistance pathways, FFA/adipokine biology, amyloid (T2DM)
4. Pathology - Cellular/molecular mechanisms for both types; gross and microscopic morphology (insulitis, Kimmelstiel-Wilson nodules, microangiopathy, amyloid deposits); vascular pathology
5. Diagnostic Approach - ADA/WHO criteria table (FPG, 2-h OGTT, HbA1c, random glucose); prediabetes thresholds; screening guidelines; additional workup including autoantibodies, C-peptide, genetic testing, CGM
6. Management - Non-pharmacological (lifestyle, nutrition, surgery, prevention); glycemic targets; stepwise T2DM algorithm based on comorbidity profile
7. Pharmacology - All drug classes with mechanisms, doses, benefits, adverse effects, and contraindications: insulin types, metformin, sulfonylureas, meglitinides, TZDs, GLP-1 RAs, DPP-4 inhibitors, SGLT-2 inhibitors, alpha-glucosidase inhibitors, pramlintide
8. Complications - Acute (DKA, HHS, hypoglycemia with full management); chronic microvascular (retinopathy staging, nephropathy progression/histology, neuropathy types); macrovascular (CAD, stroke, PAD, diabetic foot); other (infections, NAFLD, skin)

---

---

Rheumatoid Arthritis - Complete Clinical Reference

---

1. DEFINITION

"Rheumatoid arthritis is a chronic systemic inflammatory disease of unknown etiology that primarily targets synovial tissues... systemic inflammation is thought to be responsible for a variety of coexistent comorbid conditions, including cardiovascular disease, osteoporosis, cognitive dysfunction, psychiatric disease, and cancer."

• Goldman-Cecil Medicine (International Edition)

"Rheumatoid arthritis (RA) is a chronic autoimmune disorder that principally attacks the joints, producing a nonsuppurative, proliferative, and inflammatory synovitis."

• Robbins & Cotran Pathologic Basis of Disease (10th ed.)

• Global prevalence: 0.5-1% of adults
• Approximately 3× more common in women than men (before menopause)
• Incidence peaks in the third to fourth decades but can occur at any age
• Annualized incidence: ~40/100,000 women; ~20/100,000 men
• Geographic variation: near-zero prevalence in rural Nigeria; ~5% among some Native American populations (Chippewa, Yakima, Inuit)
• RA is the leading cause of end-stage renal disease, adult-onset blindness, and non-traumatic lower extremity amputations when associated with its systemic complications

---

2. TYPES / CLASSIFICATION

By Serology

By Disease Course

Special Variants

• Early RA: Symptoms <6 months; optimal window for treatment to prevent joint damage
• Juvenile Idiopathic Arthritis (JIA): Onset <16 years; separate classification
• Felty Syndrome: RA + splenomegaly + neutropenia; severe seropositive disease
• Large Granular Lymphocyte (LGL) syndrome: Clonal expansion of NK cells/CTLs; associated with RA
• Palindromic Rheumatism: Episodic joint attacks with complete resolution between episodes; may evolve into classic RA
• ACPA-positive "pre-RA": Autoantibodies detectable up to 10 years before clinical disease onset

---

3. CAUSES / ETIOLOGY

Genetic Factors

• Heritability ~60% (monozygotic twin concordance: 12-15%; dizygotic: 2-5%)
• HLA associations (40% of genetic risk): HLA-DR alleles carrying the "shared epitope" (SE) - particularly DRB1*0401, DRB1*0404, DRB1*0101, DRB1*1402 - confer the highest risk for seropositive RA
• The shared epitope is a conserved amino acid sequence in the HLA-DR β-chain that shapes antigen presentation and may itself bind citrullinated peptides
• Non-HLA genes: >100 SNPs identified by GWAS; most implicate immune genes (PTPN22, STAT4, TRAF1-C5, IRF5, CD40, CCR6). PTPN22 is the second-strongest risk locus after HLA

Environmental Triggers

• Smoking: Strongest environmental risk factor. Induces protein citrullination in the lungs; interacts with HLA-SE to generate ACPA. Also associated with more severe disease
• Periodontal disease / Porphyromonas gingivalis: Produces its own peptidylarginine deiminase (PAD) enzyme, citrullinating host proteins → triggering ACPA generation
• Gut, lung, and oral microbiome dysbiosis: Emerging evidence links altered microbial communities to RA initiation
• Hormonal factors: Female predominance before menopause; pregnancy often ameliorates RA (remission in ~75%); postpartum flares common; oral contraceptives may be protective
• Air pollution, silica dust, infection: Associated with elevated risk

Pathogenic Sequence

1. Environmental trigger (e.g., smoking, infection) → protein citrullination at mucosal surface (lung/gut/oral)
2. ACPA generated in lymph nodes → circulates
3. ACPA deposits in joints → complement activation + immune complex formation
4. T-cell and B-cell activation → cytokine cascade → synovitis
5. Pannus formation → cartilage and bone destruction

---

4. PATHOLOGY

Molecular Pathogenesis

Histopathology / Morphology

• Synovial hyperplasia and hypertrophy (lining layer expands from 1-2 to 6-8 cell layers)
• Vascular changes: vasodilation, increased permeability, neovascularization
• Perivascular infiltration by T cells (CD4+ predominant), B cells, plasma cells, macrophages, and NK cells
• Synovial fluid: turbid, leukocytic (predominantly PMNs); WBC 5,000-75,000/mm³
• Reduction in synovial fluid viscosity (hyaluronate degradation)

• Granulation-tissue-like mass of activated synoviocytes, fibroblasts, and inflammatory cells
• Invades and destroys articular cartilage at the cartilage-pannus junction (marginal erosions)
• Releases MMPs, cathepsins, and RANKL
• Osteoclast activation at pannus-bone interface → characteristic marginal bone erosions on radiography
• Over time: fibrous ankylosis → bony ankylosis

• Central zone of fibrinoid necrosis surrounded by a palisade of elongated macrophages (epithelioid cells), then peripheral lymphocytic infiltration and fibrosis
• Thought to be initiated by small vessel vasculitis
• Occur in ~20% of seropositive patients; on extensor surfaces, pressure points, viscera

1. Synovial inflammation → synovitis
2. Pannus invades cartilage at margins → erosion of articular cartilage
3. RANKL-mediated osteoclast activation → marginal bone erosions
4. Ligament and tendon damage (tenosynovitis)
5. Joint instability → deformity
6. Fibrous ankylosis → bony ankylosis (end-stage)

OA vs RA Pathology (Comparison)

---

5. DIAGNOSTIC APPROACH

2010 ACR/EULAR Classification Criteria

Clinical Features (History and Examination)

• Morning stiffness >1 hour (cardinal feature; correlates with inflammation severity)
• Symmetric polyarthritis - classically affects MCPs, PIPs, wrists, MTPs in a symmetrical pattern
• Small joints affected preferentially (vs large joints in OA)
• DIP joints typically spared (DIP involvement suggests psoriatic arthritis or OA)
• Pain, swelling, and tenderness
• Progression: fingers → wrists → elbows → shoulders → knees → ankles → cervical spine (C1-C2)

• Ulnar deviation at MCPs - most characteristic
• Swan-neck deformity: PIP hyperextension + DIP flexion
• Boutonnière deformity: PIP flexion + DIP hyperextension
• Z-deformity of the thumb
• Baker cyst (popliteal cyst) from knee effusion
• Atlantoaxial subluxation (C1-C2): Due to transverse ligament erosion; can cause cervical cord compression and death (important pre-anesthesia consideration)

Laboratory Investigations

Imaging

• Early: periarticular soft-tissue swelling, joint-space narrowing, periarticular osteopenia
• Late: marginal erosions (pathognomonic; appear first at ulnar styloid, 2nd/3rd MCP joints), joint space loss, subluxation, deformity
• Erosions usually appear within first 1-2 years and are largely irreversible
• C-spine films: atlantoaxial subluxation (ADI >3 mm in adults); obtain before general anesthesia

• More sensitive than clinical exam for synovitis and erosions
• Power Doppler: detects active vascularity (hypervascularized pannus = active disease)
• Guides joint aspiration and injection

• Most sensitive for early synovitis, bone marrow edema (BMOE - precedes erosions), and erosions
• BMOE on MRI predicts subsequent radiographic erosion
• Useful for cervical spine assessment

Disease Activity Scoring

Differential Diagnosis of RA

---

6. MANAGEMENT

Principles of RA Management

1. Early diagnosis and early DMARD therapy - treatment within 3-6 months of symptom onset achieves best outcomes (window of opportunity)
2. Treat-to-target (T2T) strategy - target is remission (DAS28 < 2.6) or low disease activity; reassess every 1-3 months
3. All RA patients require DMARD therapy - essentially without exception
4. Escalate rapidly when treatment targets not met; do not accept inadequate control
5. Multidisciplinary approach: rheumatologist, physiotherapist, occupational therapist, podiatrist, patient education

Non-Pharmacological Management

• Exercise: Aerobic and resistance exercise improve function, reduce fatigue, cardiovascular risk, and depression without worsening joint damage. SARAH trial showed hand exercises improve grip strength
• Physiotherapy: Joint protection techniques; maintain range of motion; prevent contractures
• Occupational therapy: Assistive devices, splinting, activities of daily living modification
• Patient education: Disease understanding, self-management, smoking cessation (reduces disease severity)
• Orthoses/splinting: Reduce pain and deformity in wrists/hands
• Cardiovascular risk management: Statins, BP control (RA has 2× cardiovascular mortality)
• Vaccination: Annual influenza; pneumococcal; hepatitis B; herpes zoster (before biologic therapy); avoid live vaccines with biologics
• Osteoporosis prevention: Calcium + Vitamin D supplementation; bisphosphonates for glucocorticoid-treated patients (avoid in women of childbearing age)

Surgical Management

• Synovectomy: Remove inflamed synovium (arthroscopic or open); can delay erosion progression
• Arthroplasty (joint replacement): Hip, knee, shoulder - for end-stage joint destruction with severe functional impairment
• Tendon repair/reconstruction: For ruptured tendons
• Cervical spine fusion (C1-C2): For atlantoaxial subluxation with neurologic compromise
• Arthrodesis: Fusion of small joints for pain relief

---

7. PHARMACOLOGY

A. NSAIDs

• Risk: GI bleeding/ulceration (COX-1 inhibition → reduced gastric mucosal prostaglandins); renal impairment; hypertension
• Use with PPI in all RA patients on NSAIDs

• Less GI toxicity; shown non-inferior to naproxen/ibuprofen for cardiovascular outcomes (PRECISION trial)
• Keep at lowest effective dose; avoid in patients with high CV risk

---

B. Glucocorticoids

• Prednisone rarely >10 mg/day for articular disease
• Taper to lowest effective dose as DMARD takes effect
• Toxic risk associated with average dose >8 mg/day
• Intra-articular injection: useful for specific joint flares (ultrasound-guided for difficult joints)
• IM depot injection: ensures adherence, manages escalation period

---

C. Conventional (Traditional) DMARDs (csDMARDs)

1. Methotrexate (MTX) - Anchor Drug / First-Line

• Mechanism: Folic acid antagonist → inhibits dihydrofolate reductase → impaired purine nucleotide biosynthesis and cytokine production → immunosuppressive and anti-inflammatory effects
• Dosing: 7.5-25 mg orally or SC once weekly (weekly dosing minimizes toxicity vs daily); SC route reduces GI side effects and allows higher effective dose
• Onset: 3-6 weeks for initial response; full effect at 3-6 months
• Folic acid supplementation (1-5 mg daily) on non-MTX days reduces mucosal and hematopoietic toxicity without compromising efficacy
• Adverse effects: Mucositis, nausea/vomiting (most common), cytopenias (leukopenia, thrombocytopenia, rarely aplastic anemia), hepatotoxicity (cirrhosis with long-term use), MTX pneumonitis (acute hypersensitivity-like interstitial lung disease), teratogenicity, lymphoma (rare)
• Monitoring: CBC, LFTs, creatinine at baseline and every 4-8 weeks; chest X-ray baseline; avoid alcohol
• Contraindications: Pregnancy (teratogenic - Category X); significant renal failure (eGFR <30); severe hepatic disease; nursing; alcohol abuse

2. Hydroxychloroquine (HCQ)

• Mechanism: Antimalarial; interferes with lysosomal function → impairs antigen presentation, TLR signaling, and cytokine production; also decreases cholesterol and reduces diabetes incidence in RA patients
• Dosing: 200-400 mg/day (5 mg/kg); safe in pregnancy
• Onset: 3-6 months
• Adverse effects: GI (nausea), rash, retinal toxicity (dose-dependent; cumulative dose >400g or >5 years increases risk; annual ophthalmology exam required); cardiotoxicity (rare, QT prolongation); myopathy
• Use: Often combined with MTX and sulfasalazine (triple therapy); mild-moderate RA; safe in pregnancy

3. Sulfasalazine

• Mechanism: Unclear; anti-inflammatory and immunomodulatory effects; possibly inhibits folic acid absorption by intestinal bacteria; reduces leukocyte migration
• Dosing: Start 500 mg once or twice daily, increase to 2g/day in divided doses; max 3g/day
• Onset: 1-3 months
• Adverse effects: GI (nausea, vomiting, anorexia - most common), leukopenia, rash (sulfa allergy), reversible oligospermia
• Contraindications: Sulfa allergy; G6PD deficiency (risk of hemolysis)

4. Leflunomide

• Mechanism: Prodrug converted to active metabolite (teriflunomide) → inhibits dihydroorotate dehydrogenase (DHODH) → blocks pyrimidine de novo synthesis → inhibits proliferating lymphocytes
• Dosing: 10-20 mg once daily
• Onset: 4-8 weeks; similar efficacy to MTX
• Adverse effects: Diarrhea, elevated LFTs, hypertension, hair thinning, teratogenicity (Category X; prolonged elimination half-life - requires cholestyramine washout before pregnancy)
• Monitoring: CBC, LFTs every 4-8 weeks
• Drug interactions: Can increase MTX levels (enhanced hepatotoxicity when combined)

5. Azathioprine

• Mechanism: Purine analog → inhibits de novo purine synthesis → inhibits T and B cell proliferation
• Dosing: 1-2.5 mg/kg/day; caution with allopurinol (allopurinol inhibits xanthine oxidase → ↑ azathioprine levels → severe myelosuppression; reduce dose by 75%)
• Adverse effects: Myelosuppression, GI, hepatotoxicity, increased risk of malignancy (lymphoma), opportunistic infections

Triple csDMARD Therapy

---

D. Biologic DMARDs (bDMARDs)

1. TNF-α Inhibitors (Anti-TNF)

• Infection risk (serious): most important - reactivation of latent tuberculosis (screen with Quantiferon-TB Gold/TST before starting), fungal infections (histoplasmosis, coccidiomycosis, aspergillosis), bacterial sepsis, viral reactivation (HBV)
• Malignancy: Increased risk of lymphoma; non-melanoma skin cancers; baseline skin exam recommended
• Worsening of demyelinating disease (MS) - contraindicated in MS or optic neuritis
• Worsening or new-onset congestive heart failure - use with caution in CHF; avoid in NYHA III/IV
• Infusion/injection site reactions
• Do NOT combine two biologics (↑ infection risk without added efficacy)

2. IL-6 Receptor Inhibitors

• Tocilizumab: IV (4-8 mg/kg every 4 weeks) or SC (162 mg weekly or every 2 weeks)
• Sarilumab: SC 150-200 mg every 2 weeks
• Can be used as monotherapy (without MTX) - unique among biologics
• Suppresses CRP regardless of disease activity - monitor for signs of infection even with normal CRP

3. Abatacept (Costimulation Blocker)

• Dosing: IV (500-1000 mg every 4 weeks after loading) or SC (125 mg weekly)
• Advantages: Lower infection rate than anti-TNF; preferred in patients with prior infections, interstitial lung disease, or COPD (SC form)
• Adverse effects: Infections (less than anti-TNF); infusion reactions (mild); do NOT use with other biologics

4. Rituximab (Anti-CD20 B-cell depleting)

• Dosing: Two 1000 mg IV infusions 2 weeks apart (one course); repeat every 16-24 weeks as needed; always combined with methotrexate
• Advantages: Effective after anti-TNF failure; preferred in patients with lymphoma history or demyelinating disease; can be used in hepatitis B carriers (unlike anti-TNF, after specialist consultation)
• Adverse effects: Infusion reactions (premedicate with methylprednisolone/antihistamine/paracetamol), progressive multifocal leukoencephalopathy (PML - rare, JC virus), profound hypogammaglobulinemia with repeated courses, infections, hepatitis B reactivation (check HBV before use)
• R4RA trial: Rituximab vs tocilizumab in anti-TNF inadequate responders - synovial biopsy-driven selection improves outcomes

---

E. Targeted Synthetic DMARDs (tsDMARDs) - JAK Inhibitors

• Oral administration (vs injection for biologics)
• Rapid onset (2-4 weeks)
• Effective after biologic failure
• Baricitinib superior to adalimumab in MTX-IR patients (RA-BEAM trial)
• Upadacitinib superior to abatacept in biologic-naive patients with MTX-IR

• Infection: TB reactivation, herpes zoster reactivation (more common than biologics), bacterial pneumonia; screen for latent TB before use
• Cardiovascular risk: Post-marketing safety trial (ORAL Surveillance) showed tofacitinib associated with increased MACE (non-inferiority margin not met vs. anti-TNF in patients ≥50 years with ≥1 CV risk factor) and increased VTE and PE; FDA black-box warning - use with caution in patients with established CVD, VTE risk, or malignancy risk; reserve for failure of TNF inhibitors
• VTE (pulmonary embolism, DVT): Class-wide concern; strongest with higher doses
• Malignancy: Potential increased risk of lymphoma and other solid tumors
• Hyperlipidemia: LDL elevation seen with all JAK inhibitors
• Cytopenias: Anemia, neutropenia, thrombocytopenia
• Contraindicated with live vaccines; avoid in pregnancy

---

Treatment Algorithm (ACR/EULAR 2022)

• Methotrexate monotherapy (preferred first-line)
• Hydroxychloroquine or sulfasalazine if MTX contraindicated/not tolerated
• Add glucocorticoid bridge (low dose ≤10 mg prednisone) for rapid symptom control

• Add HCQ and/or SSZ (triple therapy) - comparable efficacy to biologic combination
• OR add/switch to a bDMARD or tsDMARD
• Choice of biologic guided by:
  • Comorbidities (TB risk → abatacept; ILD → abatacept; prior lymphoma → abatacept or tocilizumab; HBV → rituximab; HF → abatacept or IL-6i)
  • Convenience (SC vs IV)
  • Cost (biosimilars available for most anti-TNFs)

• Switch within same class (anti-TNF → anti-TNF) or different class
• Rituximab or abatacept after anti-TNF failure
• JAK inhibitor (after failure of ≥1 csDMARD and ≥1 biologic, taking CV/VTE risk into account)

• Do not stop DMARDs even in remission - RA relapse is common
• Cautious tapering of csDMARD possible in sustained remission (not recommended to stop entirely)

---

8. COMPLICATIONS

Articular Complications

• Joint destruction and deformity: Irreversible damage occurs within first 1-2 years without adequate treatment
• Functional disability: Loss of grip strength, difficulty with ADLs
• Atlantoaxial subluxation: Ligamentous erosion at C1-C2 → ADI >3 mm → cervical myelopathy, quadriplegia, death; critical before general anesthesia (flexion-extension views of cervical spine required)
• Baker (popliteal) cyst: Can rupture and mimic DVT ("pseudothrombophlebitis")
• Carpal tunnel syndrome: Tenosynovitis compresses median nerve at wrist

Extra-Articular Complications

Cardiovascular (Leading cause of death in RA)

• Accelerated atherosclerosis: Systemic inflammation promotes endothelial dysfunction, oxidative stress, and atherogenesis → 2-fold increased risk of coronary artery disease, MI, and heart failure
• Pericarditis/pericardial effusion: 50% by echo; usually asymptomatic; rarely → constrictive pericarditis
• Myocarditis, valvular disease (valve ring rheumatoid nodules)
• Increased VTE risk (pulmonary embolism, DVT)
• NSAIDs and glucocorticoids used for RA treatment further compound CV risk

Pulmonary

• Interstitial lung disease (ILD): Most common serious pulmonary complication; UIP and NSIP patterns; insidious onset; screening with HRCT; anti-fibrotic agents (nintedanib) for RA-ILD
• Pleural effusion: More common in men; usually small and asymptomatic; exudative; low glucose, low complement, high LDH
• Rheumatoid nodules in lung parenchyma (can cavitate and cause pneumothorax or hemoptysis)
• Bronchiolitis obliterans (rare, can be accelerated by gold or D-penicillamine)
• Caplan syndrome: RA + pneumoconiosis → large pulmonary nodules

Hematologic

• Anemia of chronic disease (ACD): Most common hematologic complication; normocytic normochromic; iron studies show low serum iron, low TIBC, normal/elevated ferritin; responds to disease control
• Felty Syndrome: RA + splenomegaly + neutropenia (ANC <2,000/mm³); serious, high infection risk; treat with DMARDs (MTX, rituximab); splenectomy reserved for refractory cases
• Large granular lymphocyte (LGL) syndrome: Similar to Felty; NK cell or CTL expansion; associated with RF positivity; can cause severe neutropenia
• Thrombocytosis: Reactive; correlates with disease activity
• Lymphadenopathy: Regional or generalized; correlates with disease activity

Ophthalmologic

• Keratoconjunctivitis sicca (secondary Sjögren's): Most common eye manifestation; dry eyes, dry mouth
• Episcleritis: Mild, self-limiting, superficial ocular inflammation
• Scleritis: Painful, serious; can → scleromalacia perforans (uveal tissue protrusion through weakened sclera; blindness risk)
• Peripheral ulcerative keratopathy: Corneal thinning at limbus; can perforate
• HCQ retinopathy: Dose-dependent; annual screening required

Neurological

• Entrapment neuropathies: Carpal tunnel syndrome (median nerve), tarsal tunnel syndrome (posterior tibial nerve), ulnar neuropathy
• Cervical myelopathy: From C1-C2 subluxation → progressive weakness, sensory loss, UMN signs; requires surgical stabilization
• Mononeuritis multiplex: Due to vasculitis affecting vasa nervorum → sudden focal neurological deficits
• Peripheral sensorimotor neuropathy: Mild, associated with long-standing RA and vasculitis

Renal

• Secondary amyloidosis (AA amyloidosis): Complication of long-standing, poorly-controlled RA; amyloid A protein deposited in glomeruli → nephrotic syndrome → renal failure. Less common with modern biologic treatment
• Drug-induced nephrotoxicity: NSAID-related (renal ischemia), gold/D-penicillamine (membranous nephropathy)

Skin

• Subcutaneous nodules: ~20% of seropositive patients; extensor surfaces, pressure points; histology: central fibrinoid necrosis + palisading macrophages
• Accelerated nodulosis: Paradoxical increase in nodules on MTX
• Small vessel vasculitis: Digital infarcts, leukocytoclastic vasculitis, nailfold infarcts
• Pyoderma gangrenosum: Neutrophilic dermatosis; rapidly enlarging, painful ulcers
• Fragile skin: With long-term glucocorticoid use

Skeletal

• Osteopenia/Osteoporosis: Due to chronic inflammation (cytokines promote osteoclast activity), glucocorticoid use, and reduced physical activity → increased fracture risk. Calcium, Vitamin D, bisphosphonates as prophylaxis
• Juxta-articular osteopenia: Periarticular bone loss → early radiographic sign of RA

Infections

• Significantly increased susceptibility due to:
  • Immune dysregulation from RA itself
  • Immunosuppressive therapies (DMARDs, biologics, glucocorticoids)
  • Common organisms: TB, pneumocystis jirovecii (PCP), cryptococcus, aspergillus, bacterial pneumonia, herpes zoster
• Screen for and treat latent TB before biologics/JAK inhibitors
• Prophylactic co-trimoxazole for PCP in patients on high-dose immunosuppression

Malignancy

• Lymphoma (especially large B-cell and Hodgkin's): 2-4× increased risk in RA; correlates with disease activity and severity, not just with biologic therapy
• Non-melanoma skin cancer: Increased with azathioprine and anti-TNF
• Lung cancer: Associated with smoking (shared risk factor with RA)

---

Summary: Key Points

---

• Goldman-Cecil Medicine (International Edition) - Chapter 243: Rheumatoid Arthritis (Iain McInnes)
• Robbins & Cotran Pathologic Basis of Disease (10th ed.) - Chapter 26: Bones, Joints, and Soft Tissue Tumors
• Lippincott Illustrated Reviews: Pharmacology (7th ed.) - Chapter 40: Agents Used in Gout and Rheumatoid Arthritis
• Firestein & Kelley's Textbook of Rheumatology (10th ed.) - Chapters 12, 15, 17: RA Pathogenesis and Therapy
• Katzung's Basic and Clinical Pharmacology (16th ed.) - Chapter 36: DMARDs

Recent Evidence Notes:

• A 2024 systematic review (PMID 38814660, Modern Rheumatology) supporting updated Japan College of Rheumatology guidelines confirms the superiority of combination csDMARD + biologic strategies over monotherapy for moderate-to-high activity RA.
• A 2026 meta-analysis (PMID 41188120, Annals of the Rheumatic Diseases) on "difficult-to-treat RA" estimates ~10-15% of RA patients remain refractory to multiple biologic/JAK inhibitor strategies - emerging therapies include CAR-T cell therapy (PMID 39754644) showing early promise in autoimmune diseases.

---

Obesity - Complete Clinical Reference

---

1. DEFINITION

"For a person to develop obesity, energy intake must exceed energy expenditure in a manner that is sufficiently sustained to result in the accumulation of a large excess of triglyceride in adipose tissue. As obesity is a cumulative pathology, if energy intake exceeds energy expenditure by even as little as 7 kcal/d, this is sufficient to develop obesity over years or decades."

• Harrison's Principles of Internal Medicine (22nd Edition, 2025)

• Obesity is the second leading cause of preventable death in adults in the United States (after smoking)
• 65% of the world's population lives in countries where overweight and obesity kill more people than underweight and malnutrition
• Global pandemic: >1 billion adults have obesity (BMI ≥30); approximately 2 billion are overweight (BMI ≥25)
• Prevalence among adolescents (16-19 years) in the United States: ~20%

---

2. TYPES / CLASSIFICATION

A. By BMI (WHO Classification)

B. By Fat Distribution (Phenotype)

C. By Etiology

---

3. CAUSES / ETIOLOGY

Genetic Factors

• Heritability of BMI: ~40-70% from twin and adoption studies; concordance rates for BMI in identical twins raised apart are very similar, confirming strong genetic determination
• Obesity is polygenic in >95% of cases: hundreds of common variants each with small effects on BMI
• HLA and metabolic gene variants identified by GWAS include variants near FTO, MC4R, TMEM18, GNPDA2, BDNF, NEGR1, FAIM2 - most act through central nervous system regulation of food intake and satiety

• Leptin deficiency (LEP mutations): Profound hyperphagia and severe early-onset obesity; treatable with exogenous leptin (setmelanotide, metreleptin)
• Leptin receptor mutations (LEPR): Same phenotype; not amenable to leptin therapy
• Pro-opiomelanocortin (POMC) deficiency: Hyperphagia, early-onset obesity, adrenal insufficiency, red hair; responsive to setmelanotide (MC4R agonist)
• Melanocortin-4 receptor mutations (MC4R): Most common monogenic cause (~5% of severe early-onset obesity); autosomal dominant; increased lean mass and food intake
• PCSK1 mutations: POMC processing defect → pro-insulin excess, hyperphagia

• Prader-Willi syndrome (PWS): Paternal 15q11-13 deletion; hyperphagia, intellectual disability, hypogonadism, short stature; behavioral abnormalities overlap with autism-like features; reduced oxytocin signaling
• Bardet-Biedl syndrome: AR; obesity, retinal dystrophy, polydactyly, renal anomalies, cognitive impairment
• Alström syndrome: AR; obesity, retinal dystrophy, cardiomyopathy, T2DM

Neurobiological/Hypothalamic Regulation

• Arcuate nucleus (ARC): Contains two opposing neuronal populations:
  • Orexigenic (appetite-stimulating): NPY/AgRP neurons - stimulated by ghrelin, fasting; inhibited by leptin, insulin
  • Anorexigenic (appetite-suppressing): POMC/CART neurons - stimulated by leptin, insulin; produce α-MSH → acts on MC4R → satiety
• Melanocortin pathway (MC4R): Central to obesity regulation; α-MSH from POMC neurons binds MC4R → reduces food intake and increases energy expenditure; AgRP is an endogenous MC4R antagonist
• Leptin: Secreted by white adipose tissue proportional to fat mass → acts on hypothalamic POMC neurons → suppresses appetite and increases energy expenditure. In common obesity, leptin resistance develops (not deficiency) - high circulating leptin but impaired signaling
• Ghrelin: "Hunger hormone" secreted by gastric fundus; rises before meals, falls after eating; the only gut hormone that stimulates appetite; falls after RYGB but not after gastric banding
• Gut satiety hormones (post-meal): GLP-1, PYY, CCK, GIP - signal satiety to hypothalamus; stimulated after RYGB
• Insulin: Anorexigenic in the brain; peripheral insulin resistance is key to T2DM association

Environmental / Behavioral Factors

• Food environment: Increased availability and affordability of energy-dense, highly palatable, ultra-processed foods; aggressive marketing; supersized portions; ubiquitous food access
• Physical inactivity: Mechanization of work and domestic life; sedentary occupations; screen time; motorized transport
• Thermoregulation: Artificial heating and cooling reduces energy spent on thermoregulation
• Sleep deprivation: Increases ghrelin, decreases leptin → increased hunger and caloric intake; increases cortisol → insulin resistance; disturbs circadian rhythms of metabolic hormones
• Stress and psychosocial factors: Cortisol (stress) → central fat deposition, increased appetite; emotional eating; socioeconomic disadvantage; food insecurity (paradoxically promotes obesity)
• Gut microbiome: Obese individuals have an increased Firmicutes:Bacteroidetes ratio; microbiome alterations can increase energy extraction from food and promote fat storage; bariatric surgery normalizes this ratio
• Early life programming: Maternal obesity, gestational diabetes, formula feeding, and childhood obesity strongly predict adult obesity

Secondary/Endocrine Causes (Rule out in every patient)

---

4. PATHOLOGY (PATHOPHYSIOLOGY)

Energy Imbalance at the Core

Adipose Tissue Biology

• Primary energy storage depot (triglyceride)
• Endocrine organ: secretes leptin, adiponectin, TNF-α, IL-6, resistin, angiotensinogen, PAI-1
• Adipocyte hypertrophy and hyperplasia occur with obesity
• Visceral adipose tissue (VAT): More metabolically active; greater lipolytic activity; more direct portal drainage to liver → delivers excess FFAs and pro-inflammatory cytokines directly to the liver

• Thermogenic tissue; expressed in interscapular, perirenal, and periaortic depots
• Contains uncoupling protein-1 (UCP-1) → uncouples oxidative phosphorylation → heat generation instead of ATP
• Reduced BAT activity in obesity contributes to reduced thermogenesis
• Thermogenic drug targets: β3-adrenoceptor agonists (activate BAT)

• Adipocyte hypertrophy → hypoxia → adipocyte death → macrophage infiltration (M1 polarization) → chronic low-grade sterile inflammation
• Pro-inflammatory adipokines ↑: TNF-α, IL-6, IL-1β, MCP-1, resistin, PAI-1, visfatin, leptin
• Anti-inflammatory adipokines ↓: Adiponectin (insulin-sensitizing, anti-atherogenic, anti-inflammatory - falls with obesity; low levels associated with T2DM, CVD, NASH)

Insulin Resistance Mechanism

1. Flood portal circulation → hepatic steatosis
2. Accumulate in skeletal muscle as diacylglycerol (DAG), ceramide → activate serine kinases (PKC, IKK-β)
3. Serine phosphorylation of IRS-1 → impairs insulin receptor signaling → reduced GLUT-4 translocation
4. Liver: impaired insulin-mediated suppression of gluconeogenesis → hyperglycemia
5. Compensatory hyperinsulinemia → eventual β-cell exhaustion → T2DM

Inflammatory Mechanisms

• Adipose tissue macrophages (ATMs): infiltration increases with BMI; M1/M2 imbalance
• Circulating pro-inflammatory cytokines (TNF-α, IL-6, CRP) impair endothelial function, insulin signaling, lipid metabolism
• NF-κB pathway activation → inflammatory gene transcription in multiple tissues
• This explains why obesity-associated complications are inflammatory: T2DM, CVD, NAFLD, cancer

Lipotoxicity

• Liver: → NAFLD → NASH → fibrosis/cirrhosis
• Skeletal muscle: → insulin resistance, impaired ATP generation
• Pancreas: → β-cell lipotoxicity → impaired insulin secretion
• Heart: → cardiomyopathy, diastolic dysfunction
• Kidneys: → focal segmental glomerulosclerosis

Hormonal Dysregulation in Obesity

---

5. DIAGNOSTIC APPROACH

Anthropometric Assessment

• BMI = weight (kg) / height² (m²)
• Limitations: Does not distinguish fat mass from lean mass; underestimates visceral fat in "metabolically obese, normal weight" individuals; less accurate in muscular athletes and elderly

• Men: ≥102 cm (≥40 inches) = high risk
• Women: ≥88 cm (≥35 inches) = high risk
• Asian men: ≥90 cm; Asian women: ≥80 cm

• Men: >0.9; Women: >0.85 indicates central obesity

• 0.5 indicates increased cardiometabolic risk regardless of sex or ethnicity

• Dual-energy X-ray absorptiometry (DXA): gold standard for body composition
• Bioelectrical impedance (BIA): less accurate but widely available
• Skinfold thickness measurements

Metabolic Syndrome Diagnostic Criteria (ATP III / IDF)

Evaluation of the Obese Patient

• Age of onset; trajectory; triggers; prior weight loss attempts
• Dietary habits; physical activity; sleep quality (screen for OSA)
• Medications (weight-gaining drugs)
• Family history of obesity, T2DM, CVD
• Symptoms of secondary causes: hypothyroidism (fatigue, cold intolerance), Cushing's (easy bruising, striae), PCOS (menstrual irregularity, hirsutism)
• Mental health: depression, anxiety, binge eating disorder (BED), emotional eating

• BMI, waist circumference, blood pressure (large cuff)
• Signs of secondary causes: thyroid enlargement, buffalo hump, striae, acanthosis nigricans (insulin resistance), hirsutism
• Signs of complications: edema, murmurs, respiratory examination, joint assessment
• Skin: intertrigo (skin fold infections), acanthosis nigricans (neck, axilla, groin → insulin resistance)

• Polysomnography / sleep study: If OSA suspected (snoring, witnessed apneas, Epworth Sleepiness Scale score ≥10)
• Liver biopsy: Gold standard for NAFLD/NASH staging (reserved for selected cases)
• Liver elastography (FibroScan): Non-invasive NASH fibrosis staging
• OGTT: If prediabetes/GDM suspected
• Echocardiography: If cardiac symptoms or cardiomyopathy suspected
• Abdominal ultrasound: Fatty liver, gallstones
• Pelvic ultrasound: PCOS diagnosis

Tools for Severity and Comorbidity Staging

• Edmonton Obesity Staging System (EOSS): Stages 0-4 based on physical, metabolic, psychological, and functional impairment - better predictor of mortality than BMI alone
• Obesity-Related Co-morbidity (Organ System Review) as per Harrison's 22e:

---

6. MANAGEMENT

Principles

1. Obesity is a chronic disease requiring long-term management, not a lifestyle choice
2. Even modest weight loss (5-10%) significantly reduces comorbidities
3. Three complementary modalities: lifestyle intervention → pharmacotherapy → bariatric surgery
4. Treatment intensity should match degree of obesity and comorbidity burden (EOSS staging)
5. Addressing psychological factors, sleep, and the social determinants of health is essential
6. Avoid weight-gain promoting medications when possible; switch to weight-neutral alternatives

Goals of Treatment (AHA/ACC/TOS Guidelines)

• 5-10% weight loss: Reduces blood pressure, improves glycemia, lipids, OSA, joint pain, quality of life
• >10-15% weight loss: Remission of T2DM possible; substantial cardiovascular risk reduction
• >20% (bariatric surgery): Durable T2DM remission, improved survival

A. Lifestyle Intervention (First-Line for All Patients)

• Caloric restriction: 500-750 kcal/day deficit → ~0.5-0.75 kg/week weight loss; individualized
• Multiple dietary approaches effective (low-fat, low-carbohydrate, Mediterranean, DASH) - adherence determines success more than type
• Reduce ultra-processed foods, sugar-sweetened beverages, refined carbohydrates
• Increase dietary fiber, protein (promotes satiety, preserves lean mass)
• Very Low Calorie Diets (VLCD): <800 kcal/day → 1.5-2 kg/week; medically supervised; reserved for rapid pre-surgical weight loss
• Intermittent fasting: alternate-day fasting or time-restricted eating; non-inferior to caloric restriction for short-term weight loss

• ≥150 min/week moderate-intensity aerobic exercise (minimum recommendation)
• ≥300 min/week optimal for weight loss maintenance
• Resistance/strength training: preserves lean mass during weight loss; improves insulin sensitivity
• Reduces visceral fat even without significant weight loss
• NEAT (non-exercise activity thermogenesis): standing, walking, fidgeting; important contributor to daily energy expenditure

• Regular self-monitoring of food intake, physical activity, and weight
• Goal-setting, problem-solving, stimulus control, cognitive behavioral therapy (CBT)
• Weekly contact with trained interventionist during active weight loss
• The Look AHEAD trial: intensive lifestyle intervention in T2DM → 8% weight loss at 1 year
• Comprehensive programs achieve mean weight loss of 5-8%, with ~60-65% of patients losing ≥5%
• Weight regain is common without ongoing maintenance support (most regain within 3-5 years)

• Sleep optimization: ≥7 hours/night; treat OSA (weight loss improves OSA but OSA treatment helps weight loss too)
• Stress management; screen and treat depression and anxiety (bidirectional relationship with obesity)
• Limit alcohol (>100 kcal/drink; impairs weight loss; worsens NAFLD)
• Screen for binge eating disorder (BED): cognitive behavioral therapy + pharmacotherapy (lisdexamfetamine approved for BED)

---

7. PHARMACOTHERAPY

Indications (FDA / Guidelines)

• BMI ≥30 kg/m² without weight-related comorbidities
• BMI ≥27 kg/m² with at least one obesity-related comorbidity (T2DM, hypertension, dyslipidemia, OSA)
• After 3-6 months of lifestyle modification with insufficient response

Approved Anti-Obesity Medications (AOMs)

1. GLP-1 Receptor Agonists (Most Efficacious Class)

• Mechanism: GLP-1 receptor agonist → acts on hypothalamic satiety centers + gastric emptying inhibition + peripheral effects → reduced appetite, caloric intake, body weight; glucose-dependent insulin secretion
• Dosing: SC injection once weekly; titrate from 0.25 mg/week → 2.4 mg/week (obesity dose) over 16 weeks
• Efficacy: STEP trials: ~15% mean body weight reduction at 68 weeks (STEP 1) - most effective single-agent AOM; ~33% of patients lose ≥20%
• SELECT trial (2023): Semaglutide 2.4 mg → 20% reduction in MACE (non-fatal MI, non-fatal stroke, CV death) in obese/overweight patients without DM but with established CVD - first AOM to show CV outcome benefit
• Oral semaglutide (Rybelsus): 3-14 mg daily; approved for T2DM (not yet obesity in all markets)
• Adverse effects: GI (nausea, vomiting, diarrhea - most common; mitigate with slow titration), constipation; C-cell thyroid tumors (rodent data - contraindicated in personal/family history of MTC or MEN-2); pancreatitis (rare); injection site reactions

• Dosing: SC injection daily; titrate to 3.0 mg/day
• Efficacy: SCALE trial: ~8% mean weight loss at 1 year; ~14% achieved ≥10% weight loss
• Similar adverse effect profile to semaglutide; lower efficacy than semaglutide

• Mechanism: Dual GLP-1 and GIP receptor agonist ("twincretin") → superior weight loss than GLP-1 mono-agonists
• Dosing: SC injection once weekly; titrate 2.5 mg → up to 15 mg/week
• Efficacy: SURMOUNT-1 trial: ~20.9% mean weight loss at 72 weeks; ~57% of patients lost ≥20% of body weight - the most effective pharmacotherapy for obesity currently available
• Approved by FDA for chronic weight management (2023)
• Similar GI adverse effect profile as semaglutide

2. Orlistat (Xenical - Rx; Alli - OTC)

• Mechanism: Reversibly inhibits gastric and pancreatic lipases → blocks ~30% of dietary fat digestion and absorption → fat excreted in stool
• Dosing: 120 mg three times daily with meals (Xenical); 60 mg TID (Alli OTC); take with or within 1 hour of a fat-containing meal; if meal is skipped, skip the dose
• Efficacy: ~3-5% more weight loss than placebo; modest but consistent
• Adverse effects: GI side effects dominant: oily/fatty stools, fecal urgency, oily spotting, fecal incontinence (worse if high-fat diet ingested) - these improve with low-fat diet adherence; fat-soluble vitamin deficiency (A, D, E, K) → supplement vitamins; rare hepatotoxicity
• Advantages: Non-systemic; no cardiovascular or CNS effects; long safety record; reduces LDL cholesterol independently of weight loss; approved for adolescents ≥12 years (in some countries)

3. Phentermine (short-term only) / Phentermine-Topiramate (Qsymia)

• Mechanism: Sympathomimetic amine (amphetamine derivative) → norepinephrine release in hypothalamus → appetite suppression
• Dosing: 15-37.5 mg orally once daily (morning); DEA Schedule IV
• Limitations: FDA-approved only for short-term use (≤12 weeks); tolerance develops; high addiction potential
• Adverse effects: Hypertension, tachycardia, insomnia, dry mouth, constipation; contraindicated in CVD, hyperthyroidism, glaucoma, anxiety disorders, MAOIs

• Mechanism: Phentermine (sympathomimetic appetite suppression) + topiramate (anticonvulsant/migraine drug; reduces food intake via multiple mechanisms including glutamate receptor antagonism, carbonic anhydrase inhibition, enhanced GABA-A activity)
• Dosing: 3.75/23 mg → titrate to 15/92 mg once daily
• Efficacy: CONQUER trial: ~9-10% weight loss at 1 year (dose-dependent); ~32% of patients lost ≥10% at maximum dose
• Adverse effects: Teratogenicity (topiramate - Category X; oral clefts/fetal harm - REMS program required; negative pregnancy test monthly); cognitive/memory effects, paresthesias, taste disturbances; metabolic acidosis, kidney stones (topiramate); tachycardia/hypertension (phentermine); avoid in hyperthyroidism, glaucoma

4. Naltrexone/Bupropion (Contrave)

• Mechanism: Naltrexone (opioid antagonist) blocks the reward circuit inhibition that would normally limit POMC neuron activity → sustained activation of hypothalamic POMC neurons + bupropion (dopamine/norepinephrine reuptake inhibitor) → enhanced satiety and reduced reward-driven eating
• Dosing: Titrate over 4 weeks to 8/90 mg naltrexone/bupropion twice daily (maximum)
• Efficacy: COR trials: ~5-6% weight loss vs placebo at 1 year; ~14% lose ≥10%
• Adverse effects: Nausea, headache, constipation, dry mouth, insomnia, hypertension; black box warning for suicidality (bupropion - antidepressant class); contraindicated in seizure disorders (lowers seizure threshold), chronic opioid use, eating disorders, MAOIs; do not use in uncontrolled hypertension

5. Cellulose Hydrogel (Plenity)

• Mechanism: Oral hydrogel capsule → dissolves in stomach → hydrogel particles absorb water and expand to occupy ~25% of stomach volume → mechanical satiety
• Dosing: 3 capsules (2.25g) with 500 mL water before lunch and dinner
• Indication: BMI 25-40 kg/m² (lower threshold than other AOMs); adjunct to diet and exercise
• Efficacy: ~6% weight loss; modest; no systemic absorption; very safe profile
• Adverse effects: GI (bloating, flatulence, distension)

6. Setmelanotide (Imcivree)

• Mechanism: MC4R agonist → bypasses leptin/LEPR defects → activates melanocortin pathway directly → potent appetite suppression
• Indication: Specific rare genetic obesity syndromes: POMC deficiency, PCSK1 deficiency, LEPR deficiency, Bardet-Biedl syndrome
• Efficacy: Remarkable weight loss (40-50% in POMC/PCSK1 deficiency); first targeted obesity pharmacotherapy for monogenic obesity
• Adverse effects: Spontaneous penile erections in males (MC4R agonism), hyperpigmentation (MC1R cross-reactivity), nausea, injection site reactions

Historical/Withdrawn Drugs

• Fenfluramine/dexfenfluramine: 5-HT2 agonists; withdrawn 1997 - caused pulmonary hypertension and cardiac valvulopathy
• Sibutramine: SNRI; withdrawn 2010 - increased cardiovascular events (SCOUT trial)
• Rimonabant: CB1 endocannabinoid receptor antagonist; withdrawn 2008 - severe psychiatric side effects including suicidality
• Lorcaserin: 5-HT2C agonist; withdrawn 2020 - FDA identified increased cancer risk in post-marketing study

Drug Comparison Summary

---

B. Bariatric (Metabolic) Surgery

• BMI ≥40 kg/m² (Class III obesity)
• BMI ≥35 kg/m² with at least one serious obesity-related comorbidity (T2DM, OSA, hypertension, NASH, dyslipidemia, pseudotumor cerebri, etc.)
• BMI ≥30-34.9 kg/m² with T2DM poorly controlled with medical therapy (metabolic surgery - evidence from ADA 2022)
• Failed sustained weight loss with medical management
• Medically fit for surgery; no active substance use disorder; no uncontrolled psychiatric conditions

• Active substance abuse or alcoholism
• Uncontrolled psychiatric illness (severe eating disorder)
• Non-compliance potential (inability to follow post-op regimen)
• Malignancy with limited life expectancy
• Severe coagulopathy or high operative risk

• Mechanism: Restrictive (small gastric pouch ~30 mL) + malabsorptive (bypasses duodenum and proximal jejunum → shortened digestive absorptive length) + hormonal (early delivery of nutrients to distal ileum → ↑ GLP-1/PYY; ghrelin changes; altered bile acid signaling; microbiome shifts; neural changes)
• Weight loss: 60-80% excess weight loss (EWL); ~30-35% total body weight loss
• Metabolic outcomes: T2DM remission in 60-80% (often before significant weight loss - "metabolic surgery effect"); HTN remission ~60%; dyslipidemia improvement ~70%; OSA remission ~80%
• Complications: Anastomotic leak (1-2%), marginal ulcer, internal hernia (unique to RYGB; presents with bowel obstruction; requires surgical not conservative treatment due to risk of strangulation), dumping syndrome, vitamin/mineral deficiencies (iron, B12, folate, calcium, vitamin D), hypoglycemia (late dumping/nesidioblastosis)
• Long-term: SOS study: ~25% reduction in total mortality at 20 years vs non-surgical controls

• Mechanism: Restrictive (70-80% of stomach removed along greater curvature → narrow tubular stomach ~150 mL) + hormonal (removes ghrelin-producing fundal cells → ↓ ghrelin; ↑ GLP-1/PYY via faster gastric emptying)
• Weight loss: 50-70% EWL; ~25-30% total body weight loss
• Advantages: Simpler technically; no foreign body; no anastomosis; preserves pylorus; gastric continuity maintained; no dumping syndrome
• Complications: Leak at staple line (most feared - 1-3%); GERD worsening or new onset; stricture; hair loss; nutritional deficiencies (less than RYGB); weight regain at 5-10 years
• Current status: Has largely replaced LAGB; comparable short-term outcomes to RYGB

• Mechanism: Purely restrictive (inflatable silicone band around upper stomach → small pouch above band); hormonal effects minimal
• Weight loss: 40-50% EWL (least effective of the three)
• Complications: Band slippage/prolapse, band erosion, port malfunction, esophageal dilation; >40% require eventual band removal
• Current status: Rapidly declining worldwide due to poor long-term outcomes and high complication/revision rates

• Mechanism: Combines sleeve gastrectomy with extensive intestinal bypass (only 50-100 cm common channel)
• Weight loss: 70-90% EWL - most effective bariatric procedure
• T2DM remission: ~95%
• Complications: Highest nutritional complications (fat malabsorption → fat-soluble vitamin deficiency, protein malnutrition, frequent loose stools); higher mortality; requires lifetime vitamin/mineral supplementation and close follow-up
• Indication: Super-obesity (BMI ≥50) or failed prior bariatric procedure

• Type 2 Diabetes: Remission in 50-80% for RYGB/SG; often before significant weight loss; T2DM recurrence possible at 5-10 years (>50% long-term)
• Hypertension: Remission ~60%; improvement in almost all
• OSA: Remission ~80-85%; most significant improvement
• Dyslipidemia: Improvement in ~70-80%; triglycerides often normalize
• Mortality: RYGB associated with ~40% reduction in long-term all-cause mortality; significant reduction in CVD and cancer mortality

• Lifelong supplementation: multivitamin, calcium + vitamin D, iron (especially women of reproductive age), vitamin B12, folate
• Post-RYGB: fat-soluble vitamins (A, D, E, K)
• Post-BPD/DS: more aggressive supplementation required

C. Endoscopic Procedures (Emerging)

• Intragastric balloon: Saline-filled balloon placed endoscopically in stomach; occupies space → satiety; removed at 6 months; ~10-15% weight loss
• Endoscopic sleeve gastroplasty (ESG): Endoscopic sutures reduce stomach volume; less invasive than sleeve gastrectomy; ~15-18% total weight loss; reversible
• Aspire Assist: Aspiration of stomach contents post-meal via surgically placed tube; controversial; FDA-approved
• Duodenal-jejunal sleeve (EndoBarrier): Endoscopically placed bypass liner; metabolic improvements; investigational in most markets

---

8. COMPLICATIONS OF OBESITY

Metabolic Complications

• Obesity is the single most powerful risk factor for T2DM; 80-90% of T2DM patients are overweight/obese
• Mechanism: Visceral fat → FFA excess → insulin resistance → β-cell exhaustion
• 5-10% weight loss can normalize glycemia in prediabetes; >15% loss can induce T2DM remission

• Constellation of insulin resistance, central obesity, hypertension, dyslipidemia (high TG, low HDL), hyperglycemia
• Affects ~34% of US adults; dramatically increases CVD and T2DM risk

• Characteristic pattern: elevated triglycerides, low HDL-C, small dense LDL (even when LDL appears normal)
• Mechanism: Excess FFA → VLDL overproduction; altered lipoprotein lipase activity

• Obesity increases uric acid production and reduces renal clearance
• Risk of gout and nephrolithiasis (uric acid stones)

• Most common chronic liver disease globally; affects ~25% of obese individuals
• Spectrum: simple steatosis → NASH (inflammation + fibrosis) → cirrhosis → hepatocellular carcinoma (HCC)
• Obesity is the leading cause of ESLD not related to viral hepatitis
• Diagnosis: liver ultrasound (steatosis), elastography (fibrosis staging), liver biopsy (definitive)
• Treatment: weight loss (>7-10% reliably improves NASH); semaglutide and tirzepatide improve NASH

Cardiovascular Complications

• Obesity causes ~78% of hypertension in men and ~65% in women in US studies
• Mechanisms: hyperinsulinemia → renal sodium retention; sympathetic activation; RAAS activation; sleep apnea → nocturnal surges; structural cardiac remodeling

• 3× increased risk of CAD; obesity accelerates atherosclerosis through inflammation, dyslipidemia, hypertension, T2DM, endothelial dysfunction
• "Obesity paradox": mildly obese patients may have better short-term survival after MI (controversial)

• Both systolic (HFrEF) and diastolic (HFpEF) dysfunction
• Eccentric and concentric left ventricular hypertrophy from volume and pressure overload
• HFpEF is particularly linked to visceral obesity and metabolic syndrome
• Obesity cardiomyopathy: direct lipotoxic effect on myocardium

• Ischemic stroke risk increases with BMI; mechanisms include hypertension, atrial fibrillation, hypercoagulability
• Obesity associated with atrial fibrillation (enlarged left atrium from volume overload)

• 2-3× increased risk; mechanisms: immobility, venous hypertension, inflammatory coagulation activation, increased PAI-1 (from adipose tissue)

• The "HFpEF epidemic" closely mirrors the obesity epidemic
• Visceral fat inflammation → epicardial fat → cardiac inflammation → diastolic dysfunction

Respiratory Complications

• Most common obesity-related respiratory complication; affects 40-70% of obese patients
• Mechanism: pharyngeal fat deposition → upper airway collapsibility during sleep → repeated apneas → hypoxemia → sympathetic activation, oxidative stress → HTN, CVD, cognitive impairment, daytime somnolence
• Treatment: weight loss + CPAP; bariatric surgery → ~80-85% OSA remission

• Obesity (BMI ≥30) + daytime hypercapnia (PaCO₂ >45 mmHg) without other cause
• Mechanism: increased work of breathing from chest wall mass, reduced respiratory compliance, impaired respiratory muscle mechanics; often coexists with OSA
• Leads to: pulmonary hypertension, right heart failure (cor pulmonale), polycythemia
• Treatment: weight loss; non-invasive positive pressure ventilation (BiPAP); CPAP insufficient alone

• From OSA, OHS, and possibly direct mechanical effects of adiposity

• Obesity worsens asthma control; increases airway inflammation; reduces response to inhaled corticosteroids

• Reduced total lung capacity, FRC, FEV1, and FVC from thoracic fat mass

Gastrointestinal / Hepatic Complications

• Increased intra-abdominal pressure → LES incompetence → acid reflux; Barrett's esophagus risk increased

• Obesity increases cholesterol supersaturation of bile and gallbladder dysmotility → cholesterol gallstones
• Rapid weight loss (especially with VLCD or post-bariatric surgery) precipitates gallstone formation (ursodeoxycholic acid prophylaxis used post-surgery)

Musculoskeletal Complications

• Especially weight-bearing joints: knees, hips, lumbar spine; mechanical overload → cartilage degradation
• Each unit increase in BMI → 9-13% increase in knee osteoarthritis risk

Reproductive / Endocrine Complications

• Obesity worsens PCOS: hyperinsulinism → LH hyperstimulation → androgen overproduction → anovulation, infertility, hirsutism
• 50-80% of PCOS patients are overweight/obese

• Males: adipose aromatization of testosterone → estrogen; reduced LH/FSH → hypogonadism; scrotal hyperthermia impairs spermatogenesis
• Females: anovulation (PCOS); implantation failure; early pregnancy loss; endometrial hyperplasia

Neurological / Psychiatric Complications

• Chronic headache, papilledema, visual loss; associated with central obesity in young women
• Mechanism: increased CSF production or impaired absorption from intra-abdominal pressure transmitted to CSF via epidural venous plexus
• Treatment: weight loss (most effective); acetazolamide

• Bidirectional relationship with obesity; stigma, discrimination, body image → depression → emotional eating → weight gain; inflammatory cytokines (IL-6, TNF-α) → neuroinflammation → depression

• Midlife obesity increases risk of Alzheimer's disease and vascular dementia; metabolic syndrome, OSA, and cerebrovascular disease are mediators

Oncological Complications

Renal Complications

• Focal segmental glomerulosclerosis (FSGS) variant; proteinuria, progressive renal impairment
• Mechanism: hyperfiltration from increased renal plasma flow; RAAS activation; lipotoxicity

• Uric acid and calcium oxalate stones; risk from hyperuricemia, hypercalciuria, urinary acidification
• Post-bariatric surgery: oxalate stones from fat malabsorption → colonic hyperoxaluria

Dermatological Complications

---

Summary Table

---

• Harrison's Principles of Internal Medicine (22nd Edition, 2025) - Chapter 413: Obesity
• Schwartz's Principles of Surgery (11th ed.) - Chapter 27: Surgical Management of Obesity
• Katzung's Basic and Clinical Pharmacology (16th ed.) - Chapter 16/36: Obesity Pharmacotherapy
• Lippincott Illustrated Reviews: Pharmacology (7th ed.) - Chapter 40: Anti-obesity Agents
• Sleisenger & Fordtran's Gastrointestinal and Liver Disease - Chapter 6: Obesity
• AHA/ACC/TOS Obesity Clinical Practice Guidelines (2013, updated 2022)
• ADA Standards of Care 2024 - Metabolic Surgery

Recent Evidence Highlights:

• PMID 39761578 (Annals of Internal Medicine, 2025): Systematic review confirms GLP-1 RAs produce clinically significant weight loss in non-diabetic adults (8-15% mean weight loss)
• PMID 39952695 (Pharmacological Reviews, 2025): Comprehensive systematic review of emerging pharmacotherapies including triple agonists (GLP-1/GIP/glucagon) showing >25% weight loss in trials
• PMID 40952752 (JAMA Pediatrics, 2025): GLP-1 RAs effective and safe in children and adolescents with obesity or T2DM

1. Hepatitis - viral, alcoholic, autoimmune, drug-induced, and metabolic causes
2. Cirrhosis - compensated/decompensated disease, portal hypertension, and liver failure
3. Cholecystitis - calculous and acalculous disease, imaging, antibiotics, and surgery
4. Liver abscess - pyogenic versus amoebic abscess, drainage and antimicrobial therapy
5. Jaundice - prehepatic, hepatocellular, and obstructive patterns with a diagnostic algorithm

---

Diabetes Mellitus - Complete Clinical Reference

---

1. DEFINITION

"Diabetes mellitus is a heterogeneous spectrum of metabolic disorders, likely arising from disparate genetic and environmental factors, with a common outcome of impaired glucose homeostasis and hyperglycemia."

• Goodman & Gilman's Pharmacological Basis of Therapeutics

---

2. TYPES / CLASSIFICATION

Type 1 Diabetes Mellitus (T1DM)

• Autoimmune destruction of pancreatic β-cells leading to absolute insulin deficiency
• Accounts for 5-10% of all diabetes cases
• Previously called "juvenile-onset" or "insulin-dependent" - both terms now discouraged (can present at any age; T2DM may also need insulin)
• Strong HLA associations; most cases sporadic with defined genetic risk

Type 2 Diabetes Mellitus (T2DM)

• Characterized by impaired insulin secretion + insulin resistance
• Accounts for >90% of all diabetes cases
• Strong polygenic hereditary component; influenced by obesity and sedentary lifestyle
• May present in obese children and adolescents (not just adults)
• Previously called "adult-onset" or "non-insulin-dependent" - both terms now discouraged

Gestational Diabetes Mellitus (GDM)

• Glucose intolerance first recognized during pregnancy
• Affects ~2-10% of pregnant women; rising with obesity prevalence
• Results from impaired β-cell compensation for physiologic insulin resistance of pregnancy (placenta secretes diabetogenic hormones: growth hormone, human placental lactogen, corticotropin-releasing hormone, progesterone)
• Usually resolves after delivery; up to 60% lifetime risk of progressing to T2DM

Other Specific Types

---

3. CAUSES / ETIOLOGY

T1DM Causes

• Autoimmune: CD4+ and CD8+ T-lymphocyte-mediated destruction of β-cells; islet-cell autoantibodies (anti-GAD65, anti-IA-2, anti-ZnT8, anti-insulin antibodies) are markers
• Genetic susceptibility: HLA class II alleles (HLA-DR3, HLA-DR4, HLA-DQ) confer highest risk; MHC class I alleles (HLA-A, HLA-B, HLA-C) also contribute
• Environmental triggers: Viral infections (enterovirus, Coxsackie B, mumps, CMV, congenital rubella); dietary factors; gut microbiome alterations - precise triggers remain largely unknown
• Non-immune (LADA): Latent autoimmune diabetes in adults - slower progression than classic T1DM

T2DM Causes

1. Peripheral insulin resistance - skeletal muscle, liver, adipose tissue
2. β-cell dysfunction - inadequate compensatory insulin secretion

• Obesity (central/visceral adiposity) - the most important modifiable risk factor; risk rises with increasing BMI
• Free fatty acids (FFAs): Central adipose tissue liberates excess FFAs → diacylglycerol (DAG), ceramide, and sphingolipid accumulation → impaired insulin receptor tyrosine phosphorylation → reduced GLUT-4 translocation → hyperglycemia
• Adipokines: Leptin resistance, reduced adiponectin, elevated TNF-α and IL-6 from adipose tissue
• Amyloid deposition: IAPP (islet amyloid polypeptide) deposits in islets of patients with T2DM impairs β-cell function
• Glucotoxicity and lipotoxicity: Chronic hyperglycemia and FFAs further impair β-cell secretory capacity
• Sedentary lifestyle; aging; family history (strong polygenic component)

---

4. PATHOLOGY

Normal Glucose Homeostasis (Relevant Background)

• Fasting: liver provides glucose via glycogenolysis and gluconeogenesis (regulated by insulin-glucagon ratio); most tissues oxidize fatty acids
• Prandial: nutrient absorption triggers incretin release (GLP-1, GIP) → insulin secretion from β-cells → glucose uptake by liver, muscle, adipose tissue; hepatic glucose production suppressed
• β-cells precisely adjust insulin output to maintain euglycemia

T1DM Pathology

• HLA-DR3 or HLA-DR4 confer susceptibility; HLA-DQ alleles are even stronger risk markers
• Non-HLA genes (e.g., INS VNTR, PTPN22, CTLA4) also contribute

• Viral infections may trigger β-cell autoimmunity via molecular mimicry or bystander activation
• The "hygiene hypothesis" proposes reduced childhood microbial exposure increases risk

• CD4+ T helper cells sensitize → CD8+ cytotoxic T cells directly kill β-cells
• Islet infiltration by lymphocytes = insulitis (pathognomonic finding on biopsy)
• Progressive loss of β-cell mass over years before clinical presentation
• Autoantibodies (anti-GAD65 most sensitive; anti-IA-2, anti-ZnT8, anti-insulin) precede symptoms by years

• Reduced number and size of islets
• Lymphocytic infiltration (insulitis)
• Relative predominance of α and δ cells as β-cells are selectively destroyed

T2DM Pathology

• Reduced tyrosine phosphorylation of insulin receptor substrate (IRS) proteins
• Decreased GLUT-4 expression/translocation in skeletal muscle
• FFA intermediates (DAG, ceramide) activate serine kinases (PKC, IKK-β) that phosphorylate IRS on serine residues → impaired downstream signaling
• Liver: failure to suppress gluconeogenesis → elevated fasting glucose
• Skeletal muscle: failure of postprandial glucose uptake → elevated postprandial glucose
• Adipose tissue: failure to suppress hormone-sensitive lipase → excess FFA release

• Initially: compensatory β-cell hyperfunction and hyperinsulinemia
• Over time: ~50% of β-cell mass lost by the time of T2DM diagnosis
• Mechanisms of β-cell loss: amyloid (IAPP) deposition in islets (pathognomonic histological finding in T2DM), FFA lipotoxicity, oxidative stress, glucotoxicity, inflammatory cytokines

• Islet amyloid deposits (IAPP-derived amyloid) - virtually diagnostic of T2DM on histology
• Reduced β-cell mass
• No insulitis (unlike T1DM)
• Islet fibrosis in long-standing disease

Pathology of Chronic Complications (Morphology)

• Accelerated atherosclerosis in aorta, coronary arteries, and large peripheral vessels
• Same lesions as non-diabetics but earlier onset, more severe, more diffuse
• Contributes to MI, stroke, peripheral arterial disease

• Diffuse thickening of basement membranes (capillary walls) throughout the body
• Most clinically important in retina and kidney
• Mechanism: non-enzymatic glycation of basement membrane proteins, increased polyol pathway flux, PKC activation, oxidative stress, advanced glycation end-products (AGEs)

• Glomerular changes: diffuse glomerulosclerosis (most common) and nodular glomerulosclerosis (Kimmelstiel-Wilson nodules - pathognomonic)
• Efferent arteriolar hyalinosis (more specific for DM than afferent)
• Progression: microalbuminuria → macroalbuminuria → proteinuria → declining GFR → ESRD
• Leading cause of ESRD in the United States

• Background (non-proliferative): microaneurysms, hemorrhages, exudates, macular edema
• Proliferative: neovascularization on retinal surface (due to VEGF), vitreous hemorrhage, retinal detachment → blindness
• Leading cause of adult-onset blindness in the United States

• Distal symmetric sensorimotor polyneuropathy (most common): "stocking-glove" distribution; loss of vibration, proprioception, pain → Charcot joint, foot ulcers
• Autonomic neuropathy: orthostatic hypotension, gastroparesis, neurogenic bladder, erectile dysfunction, impaired sweating
• Cranial and focal mononeuropathies: oculomotor palsy (CN III most common), carpal tunnel syndrome

---

5. DIAGNOSTIC APPROACH

Diagnostic Criteria (ADA/WHO)

• In the absence of unequivocal hyperglycemia, criteria should be confirmed by repeat testing on a different day
• FPG: no caloric intake for at least 8 hours
• HbA1c must be performed by an NGSP-certified method traceable to the DCCT reference assay
• These criteria do not apply to gestational diabetes

Screening Recommendations (ADA)

• Age >45 years (repeat every 3 years if normal)
• BMI >25 kg/m² (or >23 in Asian descent) with any of: family history, physical inactivity, high-risk ethnicity (African American, Latino, Native American, Asian American, Pacific Islander), history of GDM, polycystic ovary syndrome, hypertension, HDL <35 mg/dL or TG >250 mg/dL, history of cardiovascular disease
• Patients with prediabetes: test annually
• Women with prior GDM: test at least every 3 years

Additional Workup

• C-peptide: Low/undetectable in T1DM; normal/elevated in T2DM or insulinoma
• Islet autoantibodies (anti-GAD65, anti-IA-2, anti-ZnT8, anti-insulin): confirm T1DM autoimmune etiology
• Urinalysis/urine albumin-to-creatinine ratio: screen for nephropathy
• Lipid panel, blood pressure: cardiovascular risk assessment
• Thyroid function: T1DM patients (increased risk of autoimmune thyroid disease)
• Genetic testing: in suspected MODY (young, non-obese, strong family history, absent autoantibodies)

Continuous Glucose Monitoring (CGM)

---

6. MANAGEMENT

Goals of Therapy

1. Alleviate symptoms (fatigue, polyuria, polydipsia, weight loss)
2. Prevent acute metabolic decompensation (DKA, HHS)
3. Prevent/delay chronic microvascular and macrovascular complications
4. Allow normal life activities and improve quality of life

• HbA1c <7% for most adults (individualized: <6.5% if achievable without significant hypoglycemia; up to <8% for elderly/frail or those with comorbidities)
• Fasting glucose: 80-130 mg/dL; peak postprandial <180 mg/dL

Non-Pharmacological Management

• Medical Nutrition Therapy (MNT): reduced caloric intake; low glycemic index foods; reduced saturated/trans fats; increased dietary fiber; carbohydrate counting (important for insulin dosing in T1DM)
• Physical activity: ≥150 min/week of moderate-intensity aerobic exercise + resistance training; exercise improves insulin sensitivity by increasing GLUT-4 translocation to skeletal muscle plasma membranes
• Weight loss in T2DM: 5-10% weight loss improves glycemia, blood pressure, lipids; ≥15% may induce T2DM remission
• Smoking cessation; self-monitoring of blood glucose; diabetes education and self-management support
• Bariatric surgery: highly effective for T2DM remission in eligible obese patients (BMI ≥35)

• Intensive lifestyle intervention (DPP trial): reduces incident diabetes by ~58%
• Metformin (1g BID): reduces risk by ~25%
• Acarbose (up to 100mg TID): reduces short-term risk by ~25%
• Liraglutide 3 mg/day: reduces incident diabetes by ~20% in overweight patients with prediabetes

---

7. PHARMACOLOGY

A. INSULIN THERAPY

• T1DM regimens: Basal-bolus (multiple daily injections) or continuous subcutaneous insulin infusion (CSII/insulin pump); closed-loop systems (artificial pancreas) increasingly available
• T2DM: Start with basal insulin (bedtime glargine/detemir); add prandial insulin as needed

---

B. NON-INSULIN AGENTS (T2DM)

1. Biguanides - Metformin

• Mechanism: Activates AMPK → inhibits hepatic gluconeogenesis; also reduces intestinal glucose absorption; mild peripheral insulin sensitization; does NOT stimulate insulin secretion
• Benefits: No hypoglycemia, mild weight loss or neutral, cardioprotective data, inexpensive, may prevent diabetes
• Adverse effects: GI (nausea, diarrhea - reduce with titration); lactic acidosis (rare, mainly in renal impairment); Vitamin B12 deficiency with long-term use
• Contraindications: eGFR <30 mL/min; hold before iodinated contrast/surgery
• Dosing: Start 500mg daily with meals; max 2,550 mg/day in divided doses

2. Sulfonylureas (2nd generation)

• Drugs: Glimepiride, Glipizide, Glyburide
• Mechanism: Bind SUR1 subunit of β-cell K_ATP channel → channel closure → membrane depolarization → Ca²+ influx → insulin secretion (glucose-independent)
• Benefits: Potent glucose lowering; inexpensive
• Adverse effects: Hypoglycemia (major risk, especially glyburide), weight gain (1-3 kg)
• Contraindications: T1DM, renal/hepatic insufficiency, pregnancy

3. Meglitinides (Non-sulfonylurea secretagogues)

• Drugs: Repaglinide, Nateglinide
• Mechanism: Same as sulfonylureas (K_ATP closure) but bind different site; shorter duration
• Use: Target postprandial hyperglycemia; flexible dosing (take with each meal, skip if meal skipped)
• Adverse effects: Hypoglycemia (less than sulfonylureas), weight gain

4. Thiazolidinediones (TZDs/Glitazones)

• Drugs: Pioglitazone, Rosiglitazone
• Mechanism: Agonists of PPARγ (peroxisome proliferator-activated receptor-γ) in adipose tissue → increased adiponectin, improved insulin sensitivity in muscle and liver; redistribution of fat from visceral to subcutaneous
• Benefits: No hypoglycemia; pioglitazone has modest cardiovascular benefit (PROACTIVE trial)
• Adverse effects: Weight gain (2-4 kg), fluid retention/edema, congestive heart failure exacerbation, bone fractures (increased risk in women), bladder cancer risk (pioglitazone - long-term use)
• Contraindications: Heart failure (NYHA Class III/IV), active bladder cancer

5. GLP-1 Receptor Agonists (Incretin mimetics)

• Drugs: Liraglutide, Semaglutide (daily and weekly SC), Exenatide, Dulaglutide, Albiglutide; oral semaglutide available
• Mechanism: Mimic endogenous GLP-1 → stimulate glucose-dependent insulin secretion → suppress glucagon → slow gastric emptying → central satiety signals → weight loss
• Key benefits: Significant weight loss (5-15%); CV risk reduction (liraglutide - LEADER trial; semaglutide - SUSTAIN-6); no hypoglycemia as monotherapy; GLP-1/GIP dual agonist tirzepatide (Mounjaro) shows superior glycemic and weight-loss outcomes
• Adverse effects: Nausea, vomiting, diarrhea (main); pancreatitis (rare); C-cell thyroid tumors (rodent data - contraindicated in MEN-2/medullary thyroid cancer)
• Route: Subcutaneous injection (daily or weekly); oral semaglutide available

6. DPP-4 Inhibitors (Gliptins)

• Drugs: Sitagliptin, Saxagliptin, Alogliptin, Linagliptin
• Mechanism: Inhibit dipeptidyl peptidase-4 → prevent degradation of endogenous GLP-1 and GIP → modest glucose-dependent insulin secretion and glucagon suppression
• Benefits: Weight neutral; low hypoglycemia risk; oral; renal-dose adjustment available (except linagliptin)
• Adverse effects: Nasopharyngitis, urinary tract infections; rare pancreatitis; saxagliptin: possible increased HF hospitalization (SAVOR-TIMI trial)

7. SGLT-2 Inhibitors (Gliflozins)

• Drugs: Empagliflozin, Canagliflozin, Dapagliflozin
• Mechanism: Inhibit sodium-glucose cotransporter-2 (SGLT-2) in the proximal renal tubule → reduce glucose reabsorption → glycosuria (~60-80g glucose/day excreted)
• Key benefits: Weight loss (2-3 kg); BP reduction; dramatic cardiovascular outcome benefits (empagliflozin - EMPA-REG; canagliflozin - CANVAS); nephroprotective (dapagliflozin - DAPA-CKD; canagliflozin - CREDENCE); heart failure benefit (empagliflozin - EMPEROR-Reduced)
• Adverse effects: Genitourinary infections (candidiasis, UTI); euglycemic DKA (rare but serious; hold perioperatively); volume depletion; Fournier's gangrene (rare); lower limb amputations (canagliflozin - requires monitoring); bone fractures (canagliflozin)
• Contraindications: eGFR <20-30 (varies by agent); T1DM (risk of euglycemic DKA unless specific protocols)

8. Alpha-glucosidase Inhibitors

• Drugs: Acarbose, Miglitol
• Mechanism: Competitively inhibit intestinal α-glucosidase enzymes → delay carbohydrate digestion and absorption → blunt postprandial glucose rise
• Benefits: No hypoglycemia; no systemic absorption; reduces postprandial glucose
• Adverse effects: Flatulence, bloating, diarrhea (major tolerability issue); rare hepatotoxicity with high doses

9. Amylin Analogs

• Drug: Pramlintide
• Mechanism: Synthetic amylin analog → suppresses postprandial glucagon, slows gastric emptying, central satiety → reduces postprandial glucose
• Use: Adjunct to mealtime insulin in T1DM and T2DM
• Adverse effects: Nausea; hypoglycemia (requires insulin dose reduction)

C. MANAGEMENT OF T1DM - KEY PRINCIPLES

• All T1DM patients require lifelong insulin therapy
• Preferred: basal-bolus regimen (long-acting basal + rapid-acting at meals)
• Insulin pump (CSII) with CGM provides the best glycemic control
• Closed-loop systems (hybrid artificial pancreas) are becoming standard
• Monitor for thyroid disease, celiac disease, Addison's disease (associated autoimmune conditions)
• Immunotherapy (anti-CD3; teplizumab) can delay T1DM onset in high-risk individuals (FDA-approved 2022)

D. STEPWISE APPROACH TO T2DM PHARMACOTHERAPY

1. Lifestyle modification + Metformin (unless contraindicated)
2. Add second agent based on patient profile:
   • CVD present/high ASCVD risk: Add GLP-1 RA (liraglutide, semaglutide) or SGLT-2 inhibitor (empagliflozin, canagliflozin)
   • Heart failure or CKD: Add SGLT-2 inhibitor
   • Weight loss needed: GLP-1 RA preferred
   • Minimize hypoglycemia: DPP-4 inhibitor, GLP-1 RA, or SGLT-2 inhibitor
   • Cost concern: Sulfonylurea or TZD
3. Add third agent if HbA1c remains above target
4. Progress to insulin (basal first, then basal-bolus) when oral/injectable agents insufficient

---

8. COMPLICATIONS

Acute Complications

Diabetic Ketoacidosis (DKA)

• Primarily T1DM (rare in T2DM)
• Precipitants: missed insulin, infection, stress, new diagnosis
• Pathophysiology: absolute insulin deficiency → unrestrained glucagon → hyperglycemia + accelerated lipolysis → ketogenesis (acetoacetate, β-hydroxybutyrate) → metabolic acidosis
• Clinical features: Polyuria, polydipsia, nausea/vomiting, abdominal pain, Kussmaul breathing (deep, rapid), fruity (acetone) breath, altered consciousness
• Diagnosis: Blood glucose >250 mg/dL, pH <7.3, bicarbonate <18 mEq/L, positive ketones (urine/serum), anion gap metabolic acidosis
• Management: IV fluids (0.9% NaCl first), insulin infusion (regular insulin), potassium replacement (never give insulin without ensuring K+ >3.5), treat precipitant; transition to SC insulin when anion gap closes

Hyperosmolar Hyperglycemic State (HHS)

• Primarily T2DM (older patients with residual insulin to prevent ketosis)
• Precipitants: infection, dehydration, stroke, inadequate fluid intake
• Pathophysiology: relative insulin deficiency → severe hyperglycemia → osmotic diuresis → profound dehydration without significant ketoacidosis
• Diagnosis: Blood glucose >600 mg/dL, serum osmolality >320 mOsm/kg, minimal/no ketosis, pH >7.3
• Management: Aggressive IV fluid replacement; insulin after initial resuscitation; treat precipitant; mortality higher than DKA (5-20%)

Hypoglycemia

• Most common acute complication of DM treatment (insulin, sulfonylureas)
• Blood glucose <70 mg/dL (ADA threshold); severe <54 mg/dL
• Symptoms: autonomic (sweating, tremor, palpitations, anxiety) then neuroglycopenic (confusion, seizure, coma)
• Treatment: 15g fast-acting carbohydrate (rule of 15); glucagon (SC/IM/intranasal) or IV dextrose for severe cases
• Hypoglycemia unawareness: loss of autonomic warning symptoms (adrenergic) with recurrent hypoglycemia; dangerous - managed with strict avoidance of hypoglycemia (hypoglycemia-associated autonomic failure reversal)

Chronic Complications

Microvascular Complications

• Most common cause of blindness in working-age adults in developed countries
• Stages: mild non-proliferative → moderate non-proliferative → severe non-proliferative → proliferative diabetic retinopathy (PDR)
• Features: microaneurysms, dot/blot hemorrhages, hard exudates, cotton-wool spots (nerve fiber infarcts), venous beading, intraretinal microvascular abnormalities (IRMA), neovascularization, vitreous hemorrhage, traction retinal detachment
• Diabetic macular edema (DME) can occur at any stage; most common cause of visual loss
• Screening: annual fundoscopy from diagnosis (T2DM); from 5 years after diagnosis in T1DM (or at puberty)
• Treatment: strict glycemic/BP control; anti-VEGF injections (ranibizumab, bevacizumab) for PDR and DME; laser photocoagulation; vitrectomy

• Leading cause of ESRD in the United States
• Progression: glomerular hyperfiltration → microalbuminuria (30-300 mg/day) → macroalbuminuria (>300 mg/day) → progressive decline in GFR → ESRD
• Histology: mesangial expansion, glomerular BM thickening, diffuse glomerulosclerosis, Kimmelstiel-Wilson nodules (nodular glomerulosclerosis - pathognomonic), afferent and efferent arteriolar hyalinosis (efferent more specific)
• Screening: annual urine albumin-to-creatinine ratio (UACR) and eGFR
• Treatment: ACE inhibitors or ARBs (first-line, independently of blood pressure in patients with microalbuminuria); SGLT-2 inhibitors (nephroprotective - CREDENCE, DAPA-CKD trials); strict glycemic and BP control (<130/80 mmHg)

• Most common complication of DM; affects ~50% of patients with >25-year duration
• Types:
  • Distal symmetric polyneuropathy (most common): stocking-glove sensory loss; risk of painless foot ulceration, Charcot arthropathy
  • Painful neuropathy: burning, stabbing, shooting pain (worse at night)
  • Autonomic neuropathy: gastroparesis, neurogenic bladder, erectile dysfunction, orthostatic hypotension, resting tachycardia, cardiac denervation
  • Mononeuropathies: cranial nerve palsies (CN III most common - spared pupil), carpal tunnel, meralgia paresthetica
  • Diabetic amyotrophy (Bruns-Garland): proximal lower limb weakness/pain
• Treatment: strict glycemic control (primary prevention); pain management: tricyclic antidepressants, duloxetine (FDA-approved), pregabalin/gabapentin, topical capsaicin; foot care education

Macrovascular Complications

• Coronary artery disease (CAD): 2-4x increased risk; major cause of death in T2DM; silent MI more common due to autonomic neuropathy
• Cerebrovascular disease (stroke): 2-4x increased risk of ischemic stroke
• Peripheral arterial disease (PAD): critical limb ischemia; diabetic foot syndrome (neuropathy + ischemia + infection → ulceration/gangrene → amputation)
• Diabetic foot: Leading cause of non-traumatic lower extremity amputation
• Management of macrovascular disease: antiplatelet therapy (aspirin for secondary prevention); statins (LDL target <70 mg/dL for high-risk); aggressive BP control (target <130/80 mmHg); ACE inhibitor/ARB; GLP-1 RA and SGLT-2 inhibitors for patients with established CVD

Other Complications

• Infections: Increased susceptibility (impaired neutrophil function, complement deficiency); susceptible to unusual infections: Mucormycosis (rhinocerebral), emphysematous cholecystitis, malignant otitis externa (Pseudomonas), Fournier's gangrene
• Non-alcoholic fatty liver disease (NAFLD)/NASH: Closely associated with T2DM and insulin resistance
• Skin manifestations: Acanthosis nigricans (insulin resistance), necrobiosis lipoidica diabeticorum, diabetic dermopathy, bullosis diabeticorum
• Cataracts and glaucoma: Increased risk
• Erectile dysfunction: ~50% of men with diabetes >10 years

---

Summary Table: T1DM vs T2DM

---

• Robbins & Cotran Pathologic Basis of Disease (10th ed.) - Chapter 24: Endocrine System
• Goldman-Cecil Medicine (International Edition) - Chapter 210: Diabetes Mellitus
• Goodman & Gilman's Pharmacological Basis of Therapeutics (13th ed.) - Chapter 51: Pancreatic Islet Hormones
• Harrison's Principles of Internal Medicine (22nd ed., 2025) - Chapter 415: Diabetes Mellitus
• Guyton & Hall Textbook of Medical Physiology - Chapter 79: Insulin, Glucagon, and Diabetes Mellitus
• ADA Standards of Care in Diabetes - 2024

Recent Evidence Note: A 2024 systematic review (PMID 39572394, Age & Ageing) highlights the need to individualize glycemic targets for older/frail patients with T2DM, recommending less stringent HbA1c goals (up to 8-9%) to minimize hypoglycemia risk.This comprehensive reference synthesizes content from six major medical textbooks. Here's a quick orientation to what's covered:

---

1. Definition - Precise metabolic definition with epidemiological scope
2. Types - T1DM, T2DM, GDM, and full WHO/ADA classification of "other specific types" including MODY, drug-induced, endocrinopathic, and rare genetic forms
3. Causes/Etiology - Autoimmune mechanisms (T1DM), insulin resistance pathways, FFA/adipokine biology, amyloid (T2DM)
4. Pathology - Cellular/molecular mechanisms for both types; gross and microscopic morphology (insulitis, Kimmelstiel-Wilson nodules, microangiopathy, amyloid deposits); vascular pathology
5. Diagnostic Approach - ADA/WHO criteria table (FPG, 2-h OGTT, HbA1c, random glucose); prediabetes thresholds; screening guidelines; additional workup including autoantibodies, C-peptide, genetic testing, CGM
6. Management - Non-pharmacological (lifestyle, nutrition, surgery, prevention); glycemic targets; stepwise T2DM algorithm based on comorbidity profile
7. Pharmacology - All drug classes with mechanisms, doses, benefits, adverse effects, and contraindications: insulin types, metformin, sulfonylureas, meglitinides, TZDs, GLP-1 RAs, DPP-4 inhibitors, SGLT-2 inhibitors, alpha-glucosidase inhibitors, pramlintide
8. Complications - Acute (DKA, HHS, hypoglycemia with full management); chronic microvascular (retinopathy staging, nephropathy progression/histology, neuropathy types); macrovascular (CAD, stroke, PAD, diabetic foot); other (infections, NAFLD, skin)Good. Now let me set up the workspace and write the comprehensive PPTX script.The presentation is ready. Download it here:

---

---

Rheumatoid Arthritis - Complete Clinical Reference

---

1. DEFINITION

"Rheumatoid arthritis is a chronic systemic inflammatory disease of unknown etiology that primarily targets synovial tissues... systemic inflammation is thought to be responsible for a variety of coexistent comorbid conditions, including cardiovascular disease, osteoporosis, cognitive dysfunction, psychiatric disease, and cancer."

• Goldman-Cecil Medicine (International Edition)

"Rheumatoid arthritis (RA) is a chronic autoimmune disorder that principally attacks the joints, producing a nonsuppurative, proliferative, and inflammatory synovitis."

• Robbins & Cotran Pathologic Basis of Disease (10th ed.)

• Global prevalence: 0.5-1% of adults
• Approximately 3× more common in women than men (before menopause)
• Incidence peaks in the third to fourth decades but can occur at any age
• Annualized incidence: ~40/100,000 women; ~20/100,000 men
• Geographic variation: near-zero prevalence in rural Nigeria; ~5% among some Native American populations (Chippewa, Yakima, Inuit)
• RA is the leading cause of end-stage renal disease, adult-onset blindness, and non-traumatic lower extremity amputations when associated with its systemic complications

---

2. TYPES / CLASSIFICATION

By Serology

By Disease Course

Special Variants

• Early RA: Symptoms <6 months; optimal window for treatment to prevent joint damage
• Juvenile Idiopathic Arthritis (JIA): Onset <16 years; separate classification
• Felty Syndrome: RA + splenomegaly + neutropenia; severe seropositive disease
• Large Granular Lymphocyte (LGL) syndrome: Clonal expansion of NK cells/CTLs; associated with RA
• Palindromic Rheumatism: Episodic joint attacks with complete resolution between episodes; may evolve into classic RA
• ACPA-positive "pre-RA": Autoantibodies detectable up to 10 years before clinical disease onset

---

3. CAUSES / ETIOLOGY

Genetic Factors

• Heritability ~60% (monozygotic twin concordance: 12-15%; dizygotic: 2-5%)
• HLA associations (40% of genetic risk): HLA-DR alleles carrying the "shared epitope" (SE) - particularly DRB1*0401, DRB1*0404, DRB1*0101, DRB1*1402 - confer the highest risk for seropositive RA
• The shared epitope is a conserved amino acid sequence in the HLA-DR β-chain that shapes antigen presentation and may itself bind citrullinated peptides
• Non-HLA genes: >100 SNPs identified by GWAS; most implicate immune genes (PTPN22, STAT4, TRAF1-C5, IRF5, CD40, CCR6). PTPN22 is the second-strongest risk locus after HLA

Environmental Triggers

• Smoking: Strongest environmental risk factor. Induces protein citrullination in the lungs; interacts with HLA-SE to generate ACPA. Also associated with more severe disease
• Periodontal disease / Porphyromonas gingivalis: Produces its own peptidylarginine deiminase (PAD) enzyme, citrullinating host proteins → triggering ACPA generation
• Gut, lung, and oral microbiome dysbiosis: Emerging evidence links altered microbial communities to RA initiation
• Hormonal factors: Female predominance before menopause; pregnancy often ameliorates RA (remission in ~75%); postpartum flares common; oral contraceptives may be protective
• Air pollution, silica dust, infection: Associated with elevated risk

Pathogenic Sequence

1. Environmental trigger (e.g., smoking, infection) → protein citrullination at mucosal surface (lung/gut/oral)
2. ACPA generated in lymph nodes → circulates
3. ACPA deposits in joints → complement activation + immune complex formation
4. T-cell and B-cell activation → cytokine cascade → synovitis
5. Pannus formation → cartilage and bone destruction

---

4. PATHOLOGY

Molecular Pathogenesis

Histopathology / Morphology

• Synovial hyperplasia and hypertrophy (lining layer expands from 1-2 to 6-8 cell layers)
• Vascular changes: vasodilation, increased permeability, neovascularization
• Perivascular infiltration by T cells (CD4+ predominant), B cells, plasma cells, macrophages, and NK cells
• Synovial fluid: turbid, leukocytic (predominantly PMNs); WBC 5,000-75,000/mm³
• Reduction in synovial fluid viscosity (hyaluronate degradation)

• Granulation-tissue-like mass of activated synoviocytes, fibroblasts, and inflammatory cells
• Invades and destroys articular cartilage at the cartilage-pannus junction (marginal erosions)
• Releases MMPs, cathepsins, and RANKL
• Osteoclast activation at pannus-bone interface → characteristic marginal bone erosions on radiography
• Over time: fibrous ankylosis → bony ankylosis

• Central zone of fibrinoid necrosis surrounded by a palisade of elongated macrophages (epithelioid cells), then peripheral lymphocytic infiltration and fibrosis
• Thought to be initiated by small vessel vasculitis
• Occur in ~20% of seropositive patients; on extensor surfaces, pressure points, viscera

1. Synovial inflammation → synovitis
2. Pannus invades cartilage at margins → erosion of articular cartilage
3. RANKL-mediated osteoclast activation → marginal bone erosions
4. Ligament and tendon damage (tenosynovitis)
5. Joint instability → deformity
6. Fibrous ankylosis → bony ankylosis (end-stage)

OA vs RA Pathology (Comparison)

---

5. DIAGNOSTIC APPROACH

2010 ACR/EULAR Classification Criteria

Clinical Features (History and Examination)

• Morning stiffness >1 hour (cardinal feature; correlates with inflammation severity)
• Symmetric polyarthritis - classically affects MCPs, PIPs, wrists, MTPs in a symmetrical pattern
• Small joints affected preferentially (vs large joints in OA)
• DIP joints typically spared (DIP involvement suggests psoriatic arthritis or OA)
• Pain, swelling, and tenderness
• Progression: fingers → wrists → elbows → shoulders → knees → ankles → cervical spine (C1-C2)

• Ulnar deviation at MCPs - most characteristic
• Swan-neck deformity: PIP hyperextension + DIP flexion
• Boutonnière deformity: PIP flexion + DIP hyperextension
• Z-deformity of the thumb
• Baker cyst (popliteal cyst) from knee effusion
• Atlantoaxial subluxation (C1-C2): Due to transverse ligament erosion; can cause cervical cord compression and death (important pre-anesthesia consideration)

Laboratory Investigations

Imaging

• Early: periarticular soft-tissue swelling, joint-space narrowing, periarticular osteopenia
• Late: marginal erosions (pathognomonic; appear first at ulnar styloid, 2nd/3rd MCP joints), joint space loss, subluxation, deformity
• Erosions usually appear within first 1-2 years and are largely irreversible
• C-spine films: atlantoaxial subluxation (ADI >3 mm in adults); obtain before general anesthesia

• More sensitive than clinical exam for synovitis and erosions
• Power Doppler: detects active vascularity (hypervascularized pannus = active disease)
• Guides joint aspiration and injection

• Most sensitive for early synovitis, bone marrow edema (BMOE - precedes erosions), and erosions
• BMOE on MRI predicts subsequent radiographic erosion
• Useful for cervical spine assessment

Disease Activity Scoring

Differential Diagnosis of RA

---

6. MANAGEMENT

Principles of RA Management

1. Early diagnosis and early DMARD therapy - treatment within 3-6 months of symptom onset achieves best outcomes (window of opportunity)
2. Treat-to-target (T2T) strategy - target is remission (DAS28 < 2.6) or low disease activity; reassess every 1-3 months
3. All RA patients require DMARD therapy - essentially without exception
4. Escalate rapidly when treatment targets not met; do not accept inadequate control
5. Multidisciplinary approach: rheumatologist, physiotherapist, occupational therapist, podiatrist, patient education

Non-Pharmacological Management

• Exercise: Aerobic and resistance exercise improve function, reduce fatigue, cardiovascular risk, and depression without worsening joint damage. SARAH trial showed hand exercises improve grip strength
• Physiotherapy: Joint protection techniques; maintain range of motion; prevent contractures
• Occupational therapy: Assistive devices, splinting, activities of daily living modification
• Patient education: Disease understanding, self-management, smoking cessation (reduces disease severity)
• Orthoses/splinting: Reduce pain and deformity in wrists/hands
• Cardiovascular risk management: Statins, BP control (RA has 2× cardiovascular mortality)
• Vaccination: Annual influenza; pneumococcal; hepatitis B; herpes zoster (before biologic therapy); avoid live vaccines with biologics
• Osteoporosis prevention: Calcium + Vitamin D supplementation; bisphosphonates for glucocorticoid-treated patients (avoid in women of childbearing age)

Surgical Management

• Synovectomy: Remove inflamed synovium (arthroscopic or open); can delay erosion progression
• Arthroplasty (joint replacement): Hip, knee, shoulder - for end-stage joint destruction with severe functional impairment
• Tendon repair/reconstruction: For ruptured tendons
• Cervical spine fusion (C1-C2): For atlantoaxial subluxation with neurologic compromise
• Arthrodesis: Fusion of small joints for pain relief

---

7. PHARMACOLOGY

A. NSAIDs

• Risk: GI bleeding/ulceration (COX-1 inhibition → reduced gastric mucosal prostaglandins); renal impairment; hypertension
• Use with PPI in all RA patients on NSAIDs

• Less GI toxicity; shown non-inferior to naproxen/ibuprofen for cardiovascular outcomes (PRECISION trial)
• Keep at lowest effective dose; avoid in patients with high CV risk

---

B. Glucocorticoids

• Prednisone rarely >10 mg/day for articular disease
• Taper to lowest effective dose as DMARD takes effect
• Toxic risk associated with average dose >8 mg/day
• Intra-articular injection: useful for specific joint flares (ultrasound-guided for difficult joints)
• IM depot injection: ensures adherence, manages escalation period

---

C. Conventional (Traditional) DMARDs (csDMARDs)

1. Methotrexate (MTX) - Anchor Drug / First-Line

• Mechanism: Folic acid antagonist → inhibits dihydrofolate reductase → impaired purine nucleotide biosynthesis and cytokine production → immunosuppressive and anti-inflammatory effects
• Dosing: 7.5-25 mg orally or SC once weekly (weekly dosing minimizes toxicity vs daily); SC route reduces GI side effects and allows higher effective dose
• Onset: 3-6 weeks for initial response; full effect at 3-6 months
• Folic acid supplementation (1-5 mg daily) on non-MTX days reduces mucosal and hematopoietic toxicity without compromising efficacy
• Adverse effects: Mucositis, nausea/vomiting (most common), cytopenias (leukopenia, thrombocytopenia, rarely aplastic anemia), hepatotoxicity (cirrhosis with long-term use), MTX pneumonitis (acute hypersensitivity-like interstitial lung disease), teratogenicity, lymphoma (rare)
• Monitoring: CBC, LFTs, creatinine at baseline and every 4-8 weeks; chest X-ray baseline; avoid alcohol
• Contraindications: Pregnancy (teratogenic - Category X); significant renal failure (eGFR <30); severe hepatic disease; nursing; alcohol abuse

2. Hydroxychloroquine (HCQ)

• Mechanism: Antimalarial; interferes with lysosomal function → impairs antigen presentation, TLR signaling, and cytokine production; also decreases cholesterol and reduces diabetes incidence in RA patients
• Dosing: 200-400 mg/day (5 mg/kg); safe in pregnancy
• Onset: 3-6 months
• Adverse effects: GI (nausea), rash, retinal toxicity (dose-dependent; cumulative dose >400g or >5 years increases risk; annual ophthalmology exam required); cardiotoxicity (rare, QT prolongation); myopathy
• Use: Often combined with MTX and sulfasalazine (triple therapy); mild-moderate RA; safe in pregnancy

3. Sulfasalazine

• Mechanism: Unclear; anti-inflammatory and immunomodulatory effects; possibly inhibits folic acid absorption by intestinal bacteria; reduces leukocyte migration
• Dosing: Start 500 mg once or twice daily, increase to 2g/day in divided doses; max 3g/day
• Onset: 1-3 months
• Adverse effects: GI (nausea, vomiting, anorexia - most common), leukopenia, rash (sulfa allergy), reversible oligospermia
• Contraindications: Sulfa allergy; G6PD deficiency (risk of hemolysis)

4. Leflunomide

• Mechanism: Prodrug converted to active metabolite (teriflunomide) → inhibits dihydroorotate dehydrogenase (DHODH) → blocks pyrimidine de novo synthesis → inhibits proliferating lymphocytes
• Dosing: 10-20 mg once daily
• Onset: 4-8 weeks; similar efficacy to MTX
• Adverse effects: Diarrhea, elevated LFTs, hypertension, hair thinning, teratogenicity (Category X; prolonged elimination half-life - requires cholestyramine washout before pregnancy)
• Monitoring: CBC, LFTs every 4-8 weeks
• Drug interactions: Can increase MTX levels (enhanced hepatotoxicity when combined)

5. Azathioprine

• Mechanism: Purine analog → inhibits de novo purine synthesis → inhibits T and B cell proliferation
• Dosing: 1-2.5 mg/kg/day; caution with allopurinol (allopurinol inhibits xanthine oxidase → ↑ azathioprine levels → severe myelosuppression; reduce dose by 75%)
• Adverse effects: Myelosuppression, GI, hepatotoxicity, increased risk of malignancy (lymphoma), opportunistic infections

Triple csDMARD Therapy

---

D. Biologic DMARDs (bDMARDs)

1. TNF-α Inhibitors (Anti-TNF)

• Infection risk (serious): most important - reactivation of latent tuberculosis (screen with Quantiferon-TB Gold/TST before starting), fungal infections (histoplasmosis, coccidiomycosis, aspergillosis), bacterial sepsis, viral reactivation (HBV)
• Malignancy: Increased risk of lymphoma; non-melanoma skin cancers; baseline skin exam recommended
• Worsening of demyelinating disease (MS) - contraindicated in MS or optic neuritis
• Worsening or new-onset congestive heart failure - use with caution in CHF; avoid in NYHA III/IV
• Infusion/injection site reactions
• Do NOT combine two biologics (↑ infection risk without added efficacy)

2. IL-6 Receptor Inhibitors

• Tocilizumab: IV (4-8 mg/kg every 4 weeks) or SC (162 mg weekly or every 2 weeks)
• Sarilumab: SC 150-200 mg every 2 weeks
• Can be used as monotherapy (without MTX) - unique among biologics
• Suppresses CRP regardless of disease activity - monitor for signs of infection even with normal CRP

3. Abatacept (Costimulation Blocker)

• Dosing: IV (500-1000 mg every 4 weeks after loading) or SC (125 mg weekly)
• Advantages: Lower infection rate than anti-TNF; preferred in patients with prior infections, interstitial lung disease, or COPD (SC form)
• Adverse effects: Infections (less than anti-TNF); infusion reactions (mild); do NOT use with other biologics

4. Rituximab (Anti-CD20 B-cell depleting)

• Dosing: Two 1000 mg IV infusions 2 weeks apart (one course); repeat every 16-24 weeks as needed; always combined with methotrexate
• Advantages: Effective after anti-TNF failure; preferred in patients with lymphoma history or demyelinating disease; can be used in hepatitis B carriers (unlike anti-TNF, after specialist consultation)
• Adverse effects: Infusion reactions (premedicate with methylprednisolone/antihistamine/paracetamol), progressive multifocal leukoencephalopathy (PML - rare, JC virus), profound hypogammaglobulinemia with repeated courses, infections, hepatitis B reactivation (check HBV before use)
• R4RA trial: Rituximab vs tocilizumab in anti-TNF inadequate responders - synovial biopsy-driven selection improves outcomes

---

E. Targeted Synthetic DMARDs (tsDMARDs) - JAK Inhibitors

• Oral administration (vs injection for biologics)
• Rapid onset (2-4 weeks)
• Effective after biologic failure
• Baricitinib superior to adalimumab in MTX-IR patients (RA-BEAM trial)
• Upadacitinib superior to abatacept in biologic-naive patients with MTX-IR

• Infection: TB reactivation, herpes zoster reactivation (more common than biologics), bacterial pneumonia; screen for latent TB before use
• Cardiovascular risk: Post-marketing safety trial (ORAL Surveillance) showed tofacitinib associated with increased MACE (non-inferiority margin not met vs. anti-TNF in patients ≥50 years with ≥1 CV risk factor) and increased VTE and PE; FDA black-box warning - use with caution in patients with established CVD, VTE risk, or malignancy risk; reserve for failure of TNF inhibitors
• VTE (pulmonary embolism, DVT): Class-wide concern; strongest with higher doses
• Malignancy: Potential increased risk of lymphoma and other solid tumors
• Hyperlipidemia: LDL elevation seen with all JAK inhibitors
• Cytopenias: Anemia, neutropenia, thrombocytopenia
• Contraindicated with live vaccines; avoid in pregnancy

---

Treatment Algorithm (ACR/EULAR 2022)

• Methotrexate monotherapy (preferred first-line)
• Hydroxychloroquine or sulfasalazine if MTX contraindicated/not tolerated
• Add glucocorticoid bridge (low dose ≤10 mg prednisone) for rapid symptom control

• Add HCQ and/or SSZ (triple therapy) - comparable efficacy to biologic combination
• OR add/switch to a bDMARD or tsDMARD
• Choice of biologic guided by:
  • Comorbidities (TB risk → abatacept; ILD → abatacept; prior lymphoma → abatacept or tocilizumab; HBV → rituximab; HF → abatacept or IL-6i)
  • Convenience (SC vs IV)
  • Cost (biosimilars available for most anti-TNFs)

• Switch within same class (anti-TNF → anti-TNF) or different class
• Rituximab or abatacept after anti-TNF failure
• JAK inhibitor (after failure of ≥1 csDMARD and ≥1 biologic, taking CV/VTE risk into account)

• Do not stop DMARDs even in remission - RA relapse is common
• Cautious tapering of csDMARD possible in sustained remission (not recommended to stop entirely)

---

8. COMPLICATIONS

Articular Complications

• Joint destruction and deformity: Irreversible damage occurs within first 1-2 years without adequate treatment
• Functional disability: Loss of grip strength, difficulty with ADLs
• Atlantoaxial subluxation: Ligamentous erosion at C1-C2 → ADI >3 mm → cervical myelopathy, quadriplegia, death; critical before general anesthesia (flexion-extension views of cervical spine required)
• Baker (popliteal) cyst: Can rupture and mimic DVT ("pseudothrombophlebitis")
• Carpal tunnel syndrome: Tenosynovitis compresses median nerve at wrist

Extra-Articular Complications

Cardiovascular (Leading cause of death in RA)

• Accelerated atherosclerosis: Systemic inflammation promotes endothelial dysfunction, oxidative stress, and atherogenesis → 2-fold increased risk of coronary artery disease, MI, and heart failure
• Pericarditis/pericardial effusion: 50% by echo; usually asymptomatic; rarely → constrictive pericarditis
• Myocarditis, valvular disease (valve ring rheumatoid nodules)
• Increased VTE risk (pulmonary embolism, DVT)
• NSAIDs and glucocorticoids used for RA treatment further compound CV risk

Pulmonary

• Interstitial lung disease (ILD): Most common serious pulmonary complication; UIP and NSIP patterns; insidious onset; screening with HRCT; anti-fibrotic agents (nintedanib) for RA-ILD
• Pleural effusion: More common in men; usually small and asymptomatic; exudative; low glucose, low complement, high LDH
• Rheumatoid nodules in lung parenchyma (can cavitate and cause pneumothorax or hemoptysis)
• Bronchiolitis obliterans (rare, can be accelerated by gold or D-penicillamine)
• Caplan syndrome: RA + pneumoconiosis → large pulmonary nodules

Hematologic

• Anemia of chronic disease (ACD): Most common hematologic complication; normocytic normochromic; iron studies show low serum iron, low TIBC, normal/elevated ferritin; responds to disease control
• Felty Syndrome: RA + splenomegaly + neutropenia (ANC <2,000/mm³); serious, high infection risk; treat with DMARDs (MTX, rituximab); splenectomy reserved for refractory cases
• Large granular lymphocyte (LGL) syndrome: Similar to Felty; NK cell or CTL expansion; associated with RF positivity; can cause severe neutropenia
• Thrombocytosis: Reactive; correlates with disease activity
• Lymphadenopathy: Regional or generalized; correlates with disease activity

Ophthalmologic

• Keratoconjunctivitis sicca (secondary Sjögren's): Most common eye manifestation; dry eyes, dry mouth
• Episcleritis: Mild, self-limiting, superficial ocular inflammation
• Scleritis: Painful, serious; can → scleromalacia perforans (uveal tissue protrusion through weakened sclera; blindness risk)
• Peripheral ulcerative keratopathy: Corneal thinning at limbus; can perforate
• HCQ retinopathy: Dose-dependent; annual screening required

Neurological

• Entrapment neuropathies: Carpal tunnel syndrome (median nerve), tarsal tunnel syndrome (posterior tibial nerve), ulnar neuropathy
• Cervical myelopathy: From C1-C2 subluxation → progressive weakness, sensory loss, UMN signs; requires surgical stabilization
• Mononeuritis multiplex: Due to vasculitis affecting vasa nervorum → sudden focal neurological deficits
• Peripheral sensorimotor neuropathy: Mild, associated with long-standing RA and vasculitis

Renal

• Secondary amyloidosis (AA amyloidosis): Complication of long-standing, poorly-controlled RA; amyloid A protein deposited in glomeruli → nephrotic syndrome → renal failure. Less common with modern biologic treatment
• Drug-induced nephrotoxicity: NSAID-related (renal ischemia), gold/D-penicillamine (membranous nephropathy)

Skin

• Subcutaneous nodules: ~20% of seropositive patients; extensor surfaces, pressure points; histology: central fibrinoid necrosis + palisading macrophages
• Accelerated nodulosis: Paradoxical increase in nodules on MTX
• Small vessel vasculitis: Digital infarcts, leukocytoclastic vasculitis, nailfold infarcts
• Pyoderma gangrenosum: Neutrophilic dermatosis; rapidly enlarging, painful ulcers
• Fragile skin: With long-term glucocorticoid use

Skeletal

• Osteopenia/Osteoporosis: Due to chronic inflammation (cytokines promote osteoclast activity), glucocorticoid use, and reduced physical activity → increased fracture risk. Calcium, Vitamin D, bisphosphonates as prophylaxis
• Juxta-articular osteopenia: Periarticular bone loss → early radiographic sign of RA

Infections

• Significantly increased susceptibility due to:
  • Immune dysregulation from RA itself
  • Immunosuppressive therapies (DMARDs, biologics, glucocorticoids)
  • Common organisms: TB, pneumocystis jirovecii (PCP), cryptococcus, aspergillus, bacterial pneumonia, herpes zoster
• Screen for and treat latent TB before biologics/JAK inhibitors
• Prophylactic co-trimoxazole for PCP in patients on high-dose immunosuppression

Malignancy

• Lymphoma (especially large B-cell and Hodgkin's): 2-4× increased risk in RA; correlates with disease activity and severity, not just with biologic therapy
• Non-melanoma skin cancer: Increased with azathioprine and anti-TNF
• Lung cancer: Associated with smoking (shared risk factor with RA)

---

Summary: Key Points

---

• Goldman-Cecil Medicine (International Edition) - Chapter 243: Rheumatoid Arthritis (Iain McInnes)
• Robbins & Cotran Pathologic Basis of Disease (10th ed.) - Chapter 26: Bones, Joints, and Soft Tissue Tumors
• Lippincott Illustrated Reviews: Pharmacology (7th ed.) - Chapter 40: Agents Used in Gout and Rheumatoid Arthritis
• Firestein & Kelley's Textbook of Rheumatology (10th ed.) - Chapters 12, 15, 17: RA Pathogenesis and Therapy
• Katzung's Basic and Clinical Pharmacology (16th ed.) - Chapter 36: DMARDs

Recent Evidence Notes:

• A 2024 systematic review (PMID 38814660, Modern Rheumatology) supporting updated Japan College of Rheumatology guidelines confirms the superiority of combination csDMARD + biologic strategies over monotherapy for moderate-to-high activity RA.
• A 2026 meta-analysis (PMID 41188120, Annals of the Rheumatic Diseases) on "difficult-to-treat RA" estimates ~10-15% of RA patients remain refractory to multiple biologic/JAK inhibitor strategies - emerging therapies include CAR-T cell therapy (PMID 39754644) showing early promise in autoimmune diseases.Searching sources... Let me run comprehensive parallel searches across the medical library.Good. Now let me read the key obesity sections from Goldman-Cecil, Schwartz's Surgery, and Sleisenger & Fordtran in parallel.Good start. Now let me read the core obesity chapters from Schwartz's Surgery and Harrison's, plus get the pathophysiology and pharmacology content.Excellent. Now let me read the detailed obesity chapters from Schwartz's Surgery (pathophysiology, causes, pharmacotherapy) and the Harrison's/Goldman-Cecil section on obesity.Now let me read the Harrison's obesity complications section, the Katzung pharmacology section, and the Schwartz Surgery disease overview.I have rich content from Harrison's 22e, Katzung, and Schwartz's Surgery. Let me now read the Harrison's complications section and the Schwartz's pharmacotherapy section.Excellent - I now have comprehensive content from Harrison's 22e (2025), Katzung's Pharmacology, and Schwartz's Surgery. Let me compile the complete reference.

---

Obesity - Complete Clinical Reference

---

1. DEFINITION

"For a person to develop obesity, energy intake must exceed energy expenditure in a manner that is sufficiently sustained to result in the accumulation of a large excess of triglyceride in adipose tissue. As obesity is a cumulative pathology, if energy intake exceeds energy expenditure by even as little as 7 kcal/d, this is sufficient to develop obesity over years or decades."

• Harrison's Principles of Internal Medicine (22nd Edition, 2025)

• Obesity is the second leading cause of preventable death in adults in the United States (after smoking)
• 65% of the world's population lives in countries where overweight and obesity kill more people than underweight and malnutrition
• Global pandemic: >1 billion adults have obesity (BMI ≥30); approximately 2 billion are overweight (BMI ≥25)
• Prevalence among adolescents (16-19 years) in the United States: ~20%

---

2. TYPES / CLASSIFICATION

A. By BMI (WHO Classification)

B. By Fat Distribution (Phenotype)

C. By Etiology

---

3. CAUSES / ETIOLOGY

Genetic Factors

• Heritability of BMI: ~40-70% from twin and adoption studies; concordance rates for BMI in identical twins raised apart are very similar, confirming strong genetic determination
• Obesity is polygenic in >95% of cases: hundreds of common variants each with small effects on BMI
• HLA and metabolic gene variants identified by GWAS include variants near FTO, MC4R, TMEM18, GNPDA2, BDNF, NEGR1, FAIM2 - most act through central nervous system regulation of food intake and satiety

• Leptin deficiency (LEP mutations): Profound hyperphagia and severe early-onset obesity; treatable with exogenous leptin (setmelanotide, metreleptin)
• Leptin receptor mutations (LEPR): Same phenotype; not amenable to leptin therapy
• Pro-opiomelanocortin (POMC) deficiency: Hyperphagia, early-onset obesity, adrenal insufficiency, red hair; responsive to setmelanotide (MC4R agonist)
• Melanocortin-4 receptor mutations (MC4R): Most common monogenic cause (~5% of severe early-onset obesity); autosomal dominant; increased lean mass and food intake
• PCSK1 mutations: POMC processing defect → pro-insulin excess, hyperphagia

• Prader-Willi syndrome (PWS): Paternal 15q11-13 deletion; hyperphagia, intellectual disability, hypogonadism, short stature; behavioral abnormalities overlap with autism-like features; reduced oxytocin signaling
• Bardet-Biedl syndrome: AR; obesity, retinal dystrophy, polydactyly, renal anomalies, cognitive impairment
• Alström syndrome: AR; obesity, retinal dystrophy, cardiomyopathy, T2DM

Neurobiological/Hypothalamic Regulation

• Arcuate nucleus (ARC): Contains two opposing neuronal populations:
  • Orexigenic (appetite-stimulating): NPY/AgRP neurons - stimulated by ghrelin, fasting; inhibited by leptin, insulin
  • Anorexigenic (appetite-suppressing): POMC/CART neurons - stimulated by leptin, insulin; produce α-MSH → acts on MC4R → satiety
• Melanocortin pathway (MC4R): Central to obesity regulation; α-MSH from POMC neurons binds MC4R → reduces food intake and increases energy expenditure; AgRP is an endogenous MC4R antagonist
• Leptin: Secreted by white adipose tissue proportional to fat mass → acts on hypothalamic POMC neurons → suppresses appetite and increases energy expenditure. In common obesity, leptin resistance develops (not deficiency) - high circulating leptin but impaired signaling
• Ghrelin: "Hunger hormone" secreted by gastric fundus; rises before meals, falls after eating; the only gut hormone that stimulates appetite; falls after RYGB but not after gastric banding
• Gut satiety hormones (post-meal): GLP-1, PYY, CCK, GIP - signal satiety to hypothalamus; stimulated after RYGB
• Insulin: Anorexigenic in the brain; peripheral insulin resistance is key to T2DM association

Environmental / Behavioral Factors

• Food environment: Increased availability and affordability of energy-dense, highly palatable, ultra-processed foods; aggressive marketing; supersized portions; ubiquitous food access
• Physical inactivity: Mechanization of work and domestic life; sedentary occupations; screen time; motorized transport
• Thermoregulation: Artificial heating and cooling reduces energy spent on thermoregulation
• Sleep deprivation: Increases ghrelin, decreases leptin → increased hunger and caloric intake; increases cortisol → insulin resistance; disturbs circadian rhythms of metabolic hormones
• Stress and psychosocial factors: Cortisol (stress) → central fat deposition, increased appetite; emotional eating; socioeconomic disadvantage; food insecurity (paradoxically promotes obesity)
• Gut microbiome: Obese individuals have an increased Firmicutes:Bacteroidetes ratio; microbiome alterations can increase energy extraction from food and promote fat storage; bariatric surgery normalizes this ratio
• Early life programming: Maternal obesity, gestational diabetes, formula feeding, and childhood obesity strongly predict adult obesity

Secondary/Endocrine Causes (Rule out in every patient)

---

4. PATHOLOGY (PATHOPHYSIOLOGY)

Energy Imbalance at the Core

Adipose Tissue Biology

• Primary energy storage depot (triglyceride)
• Endocrine organ: secretes leptin, adiponectin, TNF-α, IL-6, resistin, angiotensinogen, PAI-1
• Adipocyte hypertrophy and hyperplasia occur with obesity
• Visceral adipose tissue (VAT): More metabolically active; greater lipolytic activity; more direct portal drainage to liver → delivers excess FFAs and pro-inflammatory cytokines directly to the liver

• Thermogenic tissue; expressed in interscapular, perirenal, and periaortic depots
• Contains uncoupling protein-1 (UCP-1) → uncouples oxidative phosphorylation → heat generation instead of ATP
• Reduced BAT activity in obesity contributes to reduced thermogenesis
• Thermogenic drug targets: β3-adrenoceptor agonists (activate BAT)

• Adipocyte hypertrophy → hypoxia → adipocyte death → macrophage infiltration (M1 polarization) → chronic low-grade sterile inflammation
• Pro-inflammatory adipokines ↑: TNF-α, IL-6, IL-1β, MCP-1, resistin, PAI-1, visfatin, leptin
• Anti-inflammatory adipokines ↓: Adiponectin (insulin-sensitizing, anti-atherogenic, anti-inflammatory - falls with obesity; low levels associated with T2DM, CVD, NASH)

Insulin Resistance Mechanism

1. Flood portal circulation → hepatic steatosis
2. Accumulate in skeletal muscle as diacylglycerol (DAG), ceramide → activate serine kinases (PKC, IKK-β)
3. Serine phosphorylation of IRS-1 → impairs insulin receptor signaling → reduced GLUT-4 translocation
4. Liver: impaired insulin-mediated suppression of gluconeogenesis → hyperglycemia
5. Compensatory hyperinsulinemia → eventual β-cell exhaustion → T2DM

Inflammatory Mechanisms

• Adipose tissue macrophages (ATMs): infiltration increases with BMI; M1/M2 imbalance
• Circulating pro-inflammatory cytokines (TNF-α, IL-6, CRP) impair endothelial function, insulin signaling, lipid metabolism
• NF-κB pathway activation → inflammatory gene transcription in multiple tissues
• This explains why obesity-associated complications are inflammatory: T2DM, CVD, NAFLD, cancer

Lipotoxicity

• Liver: → NAFLD → NASH → fibrosis/cirrhosis
• Skeletal muscle: → insulin resistance, impaired ATP generation
• Pancreas: → β-cell lipotoxicity → impaired insulin secretion
• Heart: → cardiomyopathy, diastolic dysfunction
• Kidneys: → focal segmental glomerulosclerosis

Hormonal Dysregulation in Obesity

---

5. DIAGNOSTIC APPROACH

Anthropometric Assessment

• BMI = weight (kg) / height² (m²)
• Limitations: Does not distinguish fat mass from lean mass; underestimates visceral fat in "metabolically obese, normal weight" individuals; less accurate in muscular athletes and elderly

• Men: ≥102 cm (≥40 inches) = high risk
• Women: ≥88 cm (≥35 inches) = high risk
• Asian men: ≥90 cm; Asian women: ≥80 cm

• Men: >0.9; Women: >0.85 indicates central obesity

• 0.5 indicates increased cardiometabolic risk regardless of sex or ethnicity

• Dual-energy X-ray absorptiometry (DXA): gold standard for body composition
• Bioelectrical impedance (BIA): less accurate but widely available
• Skinfold thickness measurements

Metabolic Syndrome Diagnostic Criteria (ATP III / IDF)

Evaluation of the Obese Patient

• Age of onset; trajectory; triggers; prior weight loss attempts
• Dietary habits; physical activity; sleep quality (screen for OSA)
• Medications (weight-gaining drugs)
• Family history of obesity, T2DM, CVD
• Symptoms of secondary causes: hypothyroidism (fatigue, cold intolerance), Cushing's (easy bruising, striae), PCOS (menstrual irregularity, hirsutism)
• Mental health: depression, anxiety, binge eating disorder (BED), emotional eating

• BMI, waist circumference, blood pressure (large cuff)
• Signs of secondary causes: thyroid enlargement, buffalo hump, striae, acanthosis nigricans (insulin resistance), hirsutism
• Signs of complications: edema, murmurs, respiratory examination, joint assessment
• Skin: intertrigo (skin fold infections), acanthosis nigricans (neck, axilla, groin → insulin resistance)

• Polysomnography / sleep study: If OSA suspected (snoring, witnessed apneas, Epworth Sleepiness Scale score ≥10)
• Liver biopsy: Gold standard for NAFLD/NASH staging (reserved for selected cases)
• Liver elastography (FibroScan): Non-invasive NASH fibrosis staging
• OGTT: If prediabetes/GDM suspected
• Echocardiography: If cardiac symptoms or cardiomyopathy suspected
• Abdominal ultrasound: Fatty liver, gallstones
• Pelvic ultrasound: PCOS diagnosis

Tools for Severity and Comorbidity Staging

• Edmonton Obesity Staging System (EOSS): Stages 0-4 based on physical, metabolic, psychological, and functional impairment - better predictor of mortality than BMI alone
• Obesity-Related Co-morbidity (Organ System Review) as per Harrison's 22e:

---

6. MANAGEMENT

Principles

1. Obesity is a chronic disease requiring long-term management, not a lifestyle choice
2. Even modest weight loss (5-10%) significantly reduces comorbidities
3. Three complementary modalities: lifestyle intervention → pharmacotherapy → bariatric surgery
4. Treatment intensity should match degree of obesity and comorbidity burden (EOSS staging)
5. Addressing psychological factors, sleep, and the social determinants of health is essential
6. Avoid weight-gain promoting medications when possible; switch to weight-neutral alternatives

Goals of Treatment (AHA/ACC/TOS Guidelines)

• 5-10% weight loss: Reduces blood pressure, improves glycemia, lipids, OSA, joint pain, quality of life
• >10-15% weight loss: Remission of T2DM possible; substantial cardiovascular risk reduction
• >20% (bariatric surgery): Durable T2DM remission, improved survival

A. Lifestyle Intervention (First-Line for All Patients)

• Caloric restriction: 500-750 kcal/day deficit → ~0.5-0.75 kg/week weight loss; individualized
• Multiple dietary approaches effective (low-fat, low-carbohydrate, Mediterranean, DASH) - adherence determines success more than type
• Reduce ultra-processed foods, sugar-sweetened beverages, refined carbohydrates
• Increase dietary fiber, protein (promotes satiety, preserves lean mass)
• Very Low Calorie Diets (VLCD): <800 kcal/day → 1.5-2 kg/week; medically supervised; reserved for rapid pre-surgical weight loss
• Intermittent fasting: alternate-day fasting or time-restricted eating; non-inferior to caloric restriction for short-term weight loss

• ≥150 min/week moderate-intensity aerobic exercise (minimum recommendation)
• ≥300 min/week optimal for weight loss maintenance
• Resistance/strength training: preserves lean mass during weight loss; improves insulin sensitivity
• Reduces visceral fat even without significant weight loss
• NEAT (non-exercise activity thermogenesis): standing, walking, fidgeting; important contributor to daily energy expenditure

• Regular self-monitoring of food intake, physical activity, and weight
• Goal-setting, problem-solving, stimulus control, cognitive behavioral therapy (CBT)
• Weekly contact with trained interventionist during active weight loss
• The Look AHEAD trial: intensive lifestyle intervention in T2DM → 8% weight loss at 1 year
• Comprehensive programs achieve mean weight loss of 5-8%, with ~60-65% of patients losing ≥5%
• Weight regain is common without ongoing maintenance support (most regain within 3-5 years)

• Sleep optimization: ≥7 hours/night; treat OSA (weight loss improves OSA but OSA treatment helps weight loss too)
• Stress management; screen and treat depression and anxiety (bidirectional relationship with obesity)
• Limit alcohol (>100 kcal/drink; impairs weight loss; worsens NAFLD)
• Screen for binge eating disorder (BED): cognitive behavioral therapy + pharmacotherapy (lisdexamfetamine approved for BED)

---

7. PHARMACOTHERAPY

Indications (FDA / Guidelines)

• BMI ≥30 kg/m² without weight-related comorbidities
• BMI ≥27 kg/m² with at least one obesity-related comorbidity (T2DM, hypertension, dyslipidemia, OSA)
• After 3-6 months of lifestyle modification with insufficient response

Approved Anti-Obesity Medications (AOMs)

1. GLP-1 Receptor Agonists (Most Efficacious Class)

• Mechanism: GLP-1 receptor agonist → acts on hypothalamic satiety centers + gastric emptying inhibition + peripheral effects → reduced appetite, caloric intake, body weight; glucose-dependent insulin secretion
• Dosing: SC injection once weekly; titrate from 0.25 mg/week → 2.4 mg/week (obesity dose) over 16 weeks
• Efficacy: STEP trials: ~15% mean body weight reduction at 68 weeks (STEP 1) - most effective single-agent AOM; ~33% of patients lose ≥20%
• SELECT trial (2023): Semaglutide 2.4 mg → 20% reduction in MACE (non-fatal MI, non-fatal stroke, CV death) in obese/overweight patients without DM but with established CVD - first AOM to show CV outcome benefit
• Oral semaglutide (Rybelsus): 3-14 mg daily; approved for T2DM (not yet obesity in all markets)
• Adverse effects: GI (nausea, vomiting, diarrhea - most common; mitigate with slow titration), constipation; C-cell thyroid tumors (rodent data - contraindicated in personal/family history of MTC or MEN-2); pancreatitis (rare); injection site reactions

• Dosing: SC injection daily; titrate to 3.0 mg/day
• Efficacy: SCALE trial: ~8% mean weight loss at 1 year; ~14% achieved ≥10% weight loss
• Similar adverse effect profile to semaglutide; lower efficacy than semaglutide

• Mechanism: Dual GLP-1 and GIP receptor agonist ("twincretin") → superior weight loss than GLP-1 mono-agonists
• Dosing: SC injection once weekly; titrate 2.5 mg → up to 15 mg/week
• Efficacy: SURMOUNT-1 trial: ~20.9% mean weight loss at 72 weeks; ~57% of patients lost ≥20% of body weight - the most effective pharmacotherapy for obesity currently available
• Approved by FDA for chronic weight management (2023)
• Similar GI adverse effect profile as semaglutide

2. Orlistat (Xenical - Rx; Alli - OTC)

• Mechanism: Reversibly inhibits gastric and pancreatic lipases → blocks ~30% of dietary fat digestion and absorption → fat excreted in stool
• Dosing: 120 mg three times daily with meals (Xenical); 60 mg TID (Alli OTC); take with or within 1 hour of a fat-containing meal; if meal is skipped, skip the dose
• Efficacy: ~3-5% more weight loss than placebo; modest but consistent
• Adverse effects: GI side effects dominant: oily/fatty stools, fecal urgency, oily spotting, fecal incontinence (worse if high-fat diet ingested) - these improve with low-fat diet adherence; fat-soluble vitamin deficiency (A, D, E, K) → supplement vitamins; rare hepatotoxicity
• Advantages: Non-systemic; no cardiovascular or CNS effects; long safety record; reduces LDL cholesterol independently of weight loss; approved for adolescents ≥12 years (in some countries)

3. Phentermine (short-term only) / Phentermine-Topiramate (Qsymia)

• Mechanism: Sympathomimetic amine (amphetamine derivative) → norepinephrine release in hypothalamus → appetite suppression
• Dosing: 15-37.5 mg orally once daily (morning); DEA Schedule IV
• Limitations: FDA-approved only for short-term use (≤12 weeks); tolerance develops; high addiction potential
• Adverse effects: Hypertension, tachycardia, insomnia, dry mouth, constipation; contraindicated in CVD, hyperthyroidism, glaucoma, anxiety disorders, MAOIs

• Mechanism: Phentermine (sympathomimetic appetite suppression) + topiramate (anticonvulsant/migraine drug; reduces food intake via multiple mechanisms including glutamate receptor antagonism, carbonic anhydrase inhibition, enhanced GABA-A activity)
• Dosing: 3.75/23 mg → titrate to 15/92 mg once daily
• Efficacy: CONQUER trial: ~9-10% weight loss at 1 year (dose-dependent); ~32% of patients lost ≥10% at maximum dose
• Adverse effects: Teratogenicity (topiramate - Category X; oral clefts/fetal harm - REMS program required; negative pregnancy test monthly); cognitive/memory effects, paresthesias, taste disturbances; metabolic acidosis, kidney stones (topiramate); tachycardia/hypertension (phentermine); avoid in hyperthyroidism, glaucoma

4. Naltrexone/Bupropion (Contrave)

• Mechanism: Naltrexone (opioid antagonist) blocks the reward circuit inhibition that would normally limit POMC neuron activity → sustained activation of hypothalamic POMC neurons + bupropion (dopamine/norepinephrine reuptake inhibitor) → enhanced satiety and reduced reward-driven eating
• Dosing: Titrate over 4 weeks to 8/90 mg naltrexone/bupropion twice daily (maximum)
• Efficacy: COR trials: ~5-6% weight loss vs placebo at 1 year; ~14% lose ≥10%
• Adverse effects: Nausea, headache, constipation, dry mouth, insomnia, hypertension; black box warning for suicidality (bupropion - antidepressant class); contraindicated in seizure disorders (lowers seizure threshold), chronic opioid use, eating disorders, MAOIs; do not use in uncontrolled hypertension

5. Cellulose Hydrogel (Plenity)

• Mechanism: Oral hydrogel capsule → dissolves in stomach → hydrogel particles absorb water and expand to occupy ~25% of stomach volume → mechanical satiety
• Dosing: 3 capsules (2.25g) with 500 mL water before lunch and dinner
• Indication: BMI 25-40 kg/m² (lower threshold than other AOMs); adjunct to diet and exercise
• Efficacy: ~6% weight loss; modest; no systemic absorption; very safe profile
• Adverse effects: GI (bloating, flatulence, distension)

6. Setmelanotide (Imcivree)

• Mechanism: MC4R agonist → bypasses leptin/LEPR defects → activates melanocortin pathway directly → potent appetite suppression
• Indication: Specific rare genetic obesity syndromes: POMC deficiency, PCSK1 deficiency, LEPR deficiency, Bardet-Biedl syndrome
• Efficacy: Remarkable weight loss (40-50% in POMC/PCSK1 deficiency); first targeted obesity pharmacotherapy for monogenic obesity
• Adverse effects: Spontaneous penile erections in males (MC4R agonism), hyperpigmentation (MC1R cross-reactivity), nausea, injection site reactions

Historical/Withdrawn Drugs

• Fenfluramine/dexfenfluramine: 5-HT2 agonists; withdrawn 1997 - caused pulmonary hypertension and cardiac valvulopathy
• Sibutramine: SNRI; withdrawn 2010 - increased cardiovascular events (SCOUT trial)
• Rimonabant: CB1 endocannabinoid receptor antagonist; withdrawn 2008 - severe psychiatric side effects including suicidality
• Lorcaserin: 5-HT2C agonist; withdrawn 2020 - FDA identified increased cancer risk in post-marketing study

Drug Comparison Summary

---

B. Bariatric (Metabolic) Surgery

• BMI ≥40 kg/m² (Class III obesity)
• BMI ≥35 kg/m² with at least one serious obesity-related comorbidity (T2DM, OSA, hypertension, NASH, dyslipidemia, pseudotumor cerebri, etc.)
• BMI ≥30-34.9 kg/m² with T2DM poorly controlled with medical therapy (metabolic surgery - evidence from ADA 2022)
• Failed sustained weight loss with medical management
• Medically fit for surgery; no active substance use disorder; no uncontrolled psychiatric conditions

• Active substance abuse or alcoholism
• Uncontrolled psychiatric illness (severe eating disorder)
• Non-compliance potential (inability to follow post-op regimen)
• Malignancy with limited life expectancy
• Severe coagulopathy or high operative risk

• Mechanism: Restrictive (small gastric pouch ~30 mL) + malabsorptive (bypasses duodenum and proximal jejunum → shortened digestive absorptive length) + hormonal (early delivery of nutrients to distal ileum → ↑ GLP-1/PYY; ghrelin changes; altered bile acid signaling; microbiome shifts; neural changes)
• Weight loss: 60-80% excess weight loss (EWL); ~30-35% total body weight loss
• Metabolic outcomes: T2DM remission in 60-80% (often before significant weight loss - "metabolic surgery effect"); HTN remission ~60%; dyslipidemia improvement ~70%; OSA remission ~80%
• Complications: Anastomotic leak (1-2%), marginal ulcer, internal hernia (unique to RYGB; presents with bowel obstruction; requires surgical not conservative treatment due to risk of strangulation), dumping syndrome, vitamin/mineral deficiencies (iron, B12, folate, calcium, vitamin D), hypoglycemia (late dumping/nesidioblastosis)
• Long-term: SOS study: ~25% reduction in total mortality at 20 years vs non-surgical controls

• Mechanism: Restrictive (70-80% of stomach removed along greater curvature → narrow tubular stomach ~150 mL) + hormonal (removes ghrelin-producing fundal cells → ↓ ghrelin; ↑ GLP-1/PYY via faster gastric emptying)
• Weight loss: 50-70% EWL; ~25-30% total body weight loss
• Advantages: Simpler technically; no foreign body; no anastomosis; preserves pylorus; gastric continuity maintained; no dumping syndrome
• Complications: Leak at staple line (most feared - 1-3%); GERD worsening or new onset; stricture; hair loss; nutritional deficiencies (less than RYGB); weight regain at 5-10 years
• Current status: Has largely replaced LAGB; comparable short-term outcomes to RYGB

• Mechanism: Purely restrictive (inflatable silicone band around upper stomach → small pouch above band); hormonal effects minimal
• Weight loss: 40-50% EWL (least effective of the three)
• Complications: Band slippage/prolapse, band erosion, port malfunction, esophageal dilation; >40% require eventual band removal
• Current status: Rapidly declining worldwide due to poor long-term outcomes and high complication/revision rates

• Mechanism: Combines sleeve gastrectomy with extensive intestinal bypass (only 50-100 cm common channel)
• Weight loss: 70-90% EWL - most effective bariatric procedure
• T2DM remission: ~95%
• Complications: Highest nutritional complications (fat malabsorption → fat-soluble vitamin deficiency, protein malnutrition, frequent loose stools); higher mortality; requires lifetime vitamin/mineral supplementation and close follow-up
• Indication: Super-obesity (BMI ≥50) or failed prior bariatric procedure

• Type 2 Diabetes: Remission in 50-80% for RYGB/SG; often before significant weight loss; T2DM recurrence possible at 5-10 years (>50% long-term)
• Hypertension: Remission ~60%; improvement in almost all
• OSA: Remission ~80-85%; most significant improvement
• Dyslipidemia: Improvement in ~70-80%; triglycerides often normalize
• Mortality: RYGB associated with ~40% reduction in long-term all-cause mortality; significant reduction in CVD and cancer mortality

• Lifelong supplementation: multivitamin, calcium + vitamin D, iron (especially women of reproductive age), vitamin B12, folate
• Post-RYGB: fat-soluble vitamins (A, D, E, K)
• Post-BPD/DS: more aggressive supplementation required

C. Endoscopic Procedures (Emerging)

• Intragastric balloon: Saline-filled balloon placed endoscopically in stomach; occupies space → satiety; removed at 6 months; ~10-15% weight loss
• Endoscopic sleeve gastroplasty (ESG): Endoscopic sutures reduce stomach volume; less invasive than sleeve gastrectomy; ~15-18% total weight loss; reversible
• Aspire Assist: Aspiration of stomach contents post-meal via surgically placed tube; controversial; FDA-approved
• Duodenal-jejunal sleeve (EndoBarrier): Endoscopically placed bypass liner; metabolic improvements; investigational in most markets

---

8. COMPLICATIONS OF OBESITY

Metabolic Complications

• Obesity is the single most powerful risk factor for T2DM; 80-90% of T2DM patients are overweight/obese
• Mechanism: Visceral fat → FFA excess → insulin resistance → β-cell exhaustion
• 5-10% weight loss can normalize glycemia in prediabetes; >15% loss can induce T2DM remission

• Constellation of insulin resistance, central obesity, hypertension, dyslipidemia (high TG, low HDL), hyperglycemia
• Affects ~34% of US adults; dramatically increases CVD and T2DM risk

• Characteristic pattern: elevated triglycerides, low HDL-C, small dense LDL (even when LDL appears normal)
• Mechanism: Excess FFA → VLDL overproduction; altered lipoprotein lipase activity

• Obesity increases uric acid production and reduces renal clearance
• Risk of gout and nephrolithiasis (uric acid stones)

• Most common chronic liver disease globally; affects ~25% of obese individuals
• Spectrum: simple steatosis → NASH (inflammation + fibrosis) → cirrhosis → hepatocellular carcinoma (HCC)
• Obesity is the leading cause of ESLD not related to viral hepatitis
• Diagnosis: liver ultrasound (steatosis), elastography (fibrosis staging), liver biopsy (definitive)
• Treatment: weight loss (>7-10% reliably improves NASH); semaglutide and tirzepatide improve NASH

Cardiovascular Complications

• Obesity causes ~78% of hypertension in men and ~65% in women in US studies
• Mechanisms: hyperinsulinemia → renal sodium retention; sympathetic activation; RAAS activation; sleep apnea → nocturnal surges; structural cardiac remodeling

• 3× increased risk of CAD; obesity accelerates atherosclerosis through inflammation, dyslipidemia, hypertension, T2DM, endothelial dysfunction
• "Obesity paradox": mildly obese patients may have better short-term survival after MI (controversial)

• Both systolic (HFrEF) and diastolic (HFpEF) dysfunction
• Eccentric and concentric left ventricular hypertrophy from volume and pressure overload
• HFpEF is particularly linked to visceral obesity and metabolic syndrome
• Obesity cardiomyopathy: direct lipotoxic effect on myocardium

• Ischemic stroke risk increases with BMI; mechanisms include hypertension, atrial fibrillation, hypercoagulability
• Obesity associated with atrial fibrillation (enlarged left atrium from volume overload)

• 2-3× increased risk; mechanisms: immobility, venous hypertension, inflammatory coagulation activation, increased PAI-1 (from adipose tissue)

• The "HFpEF epidemic" closely mirrors the obesity epidemic
• Visceral fat inflammation → epicardial fat → cardiac inflammation → diastolic dysfunction

Respiratory Complications

• Most common obesity-related respiratory complication; affects 40-70% of obese patients
• Mechanism: pharyngeal fat deposition → upper airway collapsibility during sleep → repeated apneas → hypoxemia → sympathetic activation, oxidative stress → HTN, CVD, cognitive impairment, daytime somnolence
• Treatment: weight loss + CPAP; bariatric surgery → ~80-85% OSA remission

• Obesity (BMI ≥30) + daytime hypercapnia (PaCO₂ >45 mmHg) without other cause
• Mechanism: increased work of breathing from chest wall mass, reduced respiratory compliance, impaired respiratory muscle mechanics; often coexists with OSA
• Leads to: pulmonary hypertension, right heart failure (cor pulmonale), polycythemia
• Treatment: weight loss; non-invasive positive pressure ventilation (BiPAP); CPAP insufficient alone

• From OSA, OHS, and possibly direct mechanical effects of adiposity

• Obesity worsens asthma control; increases airway inflammation; reduces response to inhaled corticosteroids

• Reduced total lung capacity, FRC, FEV1, and FVC from thoracic fat mass

Gastrointestinal / Hepatic Complications

• Increased intra-abdominal pressure → LES incompetence → acid reflux; Barrett's esophagus risk increased

• Obesity increases cholesterol supersaturation of bile and gallbladder dysmotility → cholesterol gallstones
• Rapid weight loss (especially with VLCD or post-bariatric surgery) precipitates gallstone formation (ursodeoxycholic acid prophylaxis used post-surgery)

Musculoskeletal Complications

• Especially weight-bearing joints: knees, hips, lumbar spine; mechanical overload → cartilage degradation
• Each unit increase in BMI → 9-13% increase in knee osteoarthritis risk

Reproductive / Endocrine Complications

• Obesity worsens PCOS: hyperinsulinism → LH hyperstimulation → androgen overproduction → anovulation, infertility, hirsutism
• 50-80% of PCOS patients are overweight/obese

• Males: adipose aromatization of testosterone → estrogen; reduced LH/FSH → hypogonadism; scrotal hyperthermia impairs spermatogenesis
• Females: anovulation (PCOS); implantation failure; early pregnancy loss; endometrial hyperplasia

Neurological / Psychiatric Complications

• Chronic headache, papilledema, visual loss; associated with central obesity in young women
• Mechanism: increased CSF production or impaired absorption from intra-abdominal pressure transmitted to CSF via epidural venous plexus
• Treatment: weight loss (most effective); acetazolamide

• Bidirectional relationship with obesity; stigma, discrimination, body image → depression → emotional eating → weight gain; inflammatory cytokines (IL-6, TNF-α) → neuroinflammation → depression

• Midlife obesity increases risk of Alzheimer's disease and vascular dementia; metabolic syndrome, OSA, and cerebrovascular disease are mediators

Oncological Complications

Renal Complications

• Focal segmental glomerulosclerosis (FSGS) variant; proteinuria, progressive renal impairment
• Mechanism: hyperfiltration from increased renal plasma flow; RAAS activation; lipotoxicity

• Uric acid and calcium oxalate stones; risk from hyperuricemia, hypercalciuria, urinary acidification
• Post-bariatric surgery: oxalate stones from fat malabsorption → colonic hyperoxaluria

Dermatological Complications

---

Summary Table

---

• Harrison's Principles of Internal Medicine (22nd Edition, 2025) - Chapter 413: Obesity
• Schwartz's Principles of Surgery (11th ed.) - Chapter 27: Surgical Management of Obesity
• Katzung's Basic and Clinical Pharmacology (16th ed.) - Chapter 16/36: Obesity Pharmacotherapy
• Lippincott Illustrated Reviews: Pharmacology (7th ed.) - Chapter 40: Anti-obesity Agents
• Sleisenger & Fordtran's Gastrointestinal and Liver Disease - Chapter 6: Obesity
• AHA/ACC/TOS Obesity Clinical Practice Guidelines (2013, updated 2022)
• ADA Standards of Care 2024 - Metabolic Surgery

Recent Evidence Highlights:

• PMID 39761578 (Annals of Internal Medicine, 2025): Systematic review confirms GLP-1 RAs produce clinically significant weight loss in non-diabetic adults (8-15% mean weight loss)
• PMID 39952695 (Pharmacological Reviews, 2025): Comprehensive systematic review of emerging pharmacotherapies including triple agonists (GLP-1/GIP/glucagon) showing >25% weight loss in trials
• PMID 40952752 (JAMA Pediatrics, 2025): GLP-1 RAs effective and safe in children and adolescents with obesity or T2DMThis is a five-topic hepatobiliary study guide. I can cover each in the requested structure:

1. Hepatitis - viral, alcoholic, autoimmune, drug-induced, and metabolic causes
2. Cirrhosis - compensated/decompensated disease, portal hypertension, and liver failure
3. Cholecystitis - calculous and acalculous disease, imaging, antibiotics, and surgery
4. Liver abscess - pyogenic versus amoebic abscess, drainage and antimicrobial therapy
5. Jaundice - prehepatic, hepatocellular, and obstructive patterns with a diagnostic algorithm

1. Hepatitis
2. Cirrhosis
3. Cholecystitis
4. Liver abscess
5. Jaundice